1 Isoform-level transcriptome-wide association uncovers extensive novel genetic risk mechanisms

- 2 for neuropsychiatric disorders in the human brain
- 3

4 AUTHORS

- 5 Arjun Bhattacharya^{1,2}, Daniel D. Vo^{3,4}, Connor Jops^{3,4}, Minsoo Kim^{5,6}, Cindy Wen⁵, Jonatan L. Hervoso⁷,
- 6 Bogdan Pasaniuc^{1,6,8±}, Michael J. Gandal^{3,4,5,6±}
- 7

8 AFFILIATIONS

- 9 1. Department of Pathology and Laboratory Medicine, David Geffen School of Medicine, University of
- 10 California, Los Angeles, California, USA
- 11 2. Institute for Quantitative and Computational Biosciences, David Geffen School of Medicine, University
- 12 of California, Los Angeles, California, USA
- 13 3. Department of Psychiatry, Perelman School of Medicine, University of Pennsylvania, Philadelphia,
- 14 Pennsylvania, USA
- 15 4. Lifespan Brain Institute at Penn Med and the Children's Hospital of Philadelphia, Philadelphia,
- 16 Pennsylvania, USA
- 17 5. Department of Psychiatry and Biobehavioral Sciences, Semel Institute, David Geffen School of
- 18 Medicine, University of California, Los Angeles, California, USA
- Department of Human Genetics, David Geffen School of Medicine, University of California, Los
 Angeles, CA, USA
- 21 7. Bioinformatics Interdepartmental Program, University of California, Los Angeles, CA, USA
- 8. Department of Computational Medicine, David Geffen School of Medicine, University of California,
- 23 Los Angeles, CA, USA
- 24 [±]Equal contribution

25

26 CORRESPONDENCE

27 Corresponding author: Arjun Bhattacharya (abtbhatt@ucla.edu)

29 ABSTRACT

Integrative methods, like colocalization and transcriptome-wide association studies (TWAS), identify transcriptomic mechanisms at only a fraction of trait-associated genetic loci from genome-wide association studies (GWAS). Here, we show that a reliance on reference functional genomics panels of only total gene expression greatly contributes to this reduced discovery. This is particularly relevant for neuropsychiatric traits, as the brain expresses extensive, complex, and unique alternative splicing patterns giving rise to multiple genetically-regulated transcript-isoforms per gene. Integrating highly correlated transcript-isoform expression with GWAS requires methodological innovations.

37

38 We introduce isoTWAS, a multivariate framework to integrate genetics, isoform-level expression, and 39 phenotypic associations in a step-wise testing framework, and evaluate it using data from the Genotype-40 Tissue Expression (GTEx) Project, PsychENCODE Consortium, and other sources. isoTWAS shows three main advantages. First, joint, multivariate modeling of isoform expression from cis-window SNPs 41 42 improves prediction by ~1.8-2.4 fold, compared to univariate modeling. Second, compared to gene-level TWAS, these improvements in prediction lead to ~1.9-2.5-fold increase in the number of testable genes 43 44 and a median of 25-70% increase in cross-validated prediction of total gene expression, with the added 45 ability to jointly capture expression and splicing mechanisms. In external validation, isoform-centric 46 models predicted gene expression at percent variance explained >1% for 50% more genes than genecentric models. Third, across 15 neuropsychiatric traits, isoTWAS increased discovery of trait 47 associations within GWAS loci over TWAS, capturing ~60% more unique loci and 95% of loci detected by 48 TWAS. Results from extensive simulations showed no increase in false discovery rate and reinforce 49 isoTWAS's advantages in prediction and trait mapping power over TWAS, especially when genetic effects 50 51 on expression vary across isoforms of the same gene. We illustrate multiple biologically-relevant 52 isoTWAS-identified trait associations undetectable by gene-level methods, including isoforms of AKT3, CUL3, and HSPD1 with schizophrenia risk, and PCLO with multiple disorders. 53

54

55 The isoTWAS framework addresses an unmet need to consider the transcriptome on the transcript-56 isoform level to increase discovery of trait associations, especially for brain-relevant traits.

57 INTRODUCTION

Over the past decade, the number of genetic associations with complex traits identified by genome-wide 58 association studies (GWAS) has increased considerably^{1,2}. However, the slow translation of these genetic 59 60 associations into concrete molecular mechanisms remains a major obstacle. As GWAS associations predominately localize within non-coding regions of the genome and are often tagged within large blocks 61 of linkage disequilibrium (LD), the first major challenge is prioritizing the underlying causal variant(s) 62 63 within a given locus and identifying their functional impact on nearby target genes. To address this, 64 numerous methods have been developed to integrate transcriptomic reference panels with GWAS to 65 prioritize genes at trait-associated loci^{3–15}. TWAS and related approaches (e.g., PrediXcan) impute the 66 cis-component of gene expression predicted by germline genetics into an association cohort, thereby 67 reducing multiple comparisons and increasing interpretability by identifying a set of genes at a locus that may underlie the genetic association^{3,4}. Despite these methodological advances, a majority of GWAS loci 68 still lack robust mechanistic interpretation¹⁶. 69

70

71 Previous integrative analyses have largely focused on aggregated measurements of total gene 72 expression but have not systematically explored the potentially large number of distinct transcript-73 isoforms that can be generated from a given genetic locus through alternative splicing. Alternative splicing is a fundamental form of tissue-specific gene regulation present in more than 90% of human genes, that 74 vastly expands the coding and regulatory potential of the genome¹⁷⁻²⁰; GENCODE v40 annotates an 75 76 average of 4 isoforms per gene (mean 4.05, standard deviation 7.28, median 1)²¹. Genes uniquely 77 expressed in the brain, which are longer and contain far more exons, undergo the greatest degree of splicing compared with other tissues and species—a mechanism contributing to the vast proteomic, 78 phenotypic, and evolutionary complexity of the human brain^{22–25}. Some genes are known to express up to 79 80 hundreds to thousands of unique isoforms in the human brain²⁵. Independent of gene expression, splicing dysregulation has been increasingly implicated as a putative disease mechanism^{24,26–30} including for 81 neuropsychiatric disorders^{10,24,27,31}. Yet, local splicing events can be computationally intensive to measure 82 and are difficult to systematically integrate across multiple distinct large-scale datasets. Splicing is often 83 84 coordinated across a gene, yielding many non-independent features that increases multiple testing

burden. In contrast, transcript-isoform abundance can now be rapidly estimated across large-scale RNAseq datasets using pseudoalignment methods^{32,33}. Furthermore, in the brain, isoform-level expression
changes have shown greater enrichment for schizophrenia heritability than gene or local splicing
changes^{22,31,34-36}. However, to fully integrate transcript-isoform quantifications with GWAS, innovative
computational methods are needed that jointly model the highly correlated transcripts of the same gene.

90

Here, we present isoform-level TWAS (isoTWAS), a flexible and scalable approach for complex trait 91 92 mapping by integrating genetic effects on isoform-level expression with GWAS. In extensive simulations 93 and real data applications in the Genotype-Tissue Expression (GTEx) Project³⁷ and the PsychENCODE 94 Consortium^{22,24}, we show that isoTWAS provides several important advantages to trait mapping. First, in the transcriptomic prediction step, the correlation between isoforms provides additional information that is 95 unavailable when only gene-level expression is measured, which can be leveraged to improve 96 prediction³⁸ accuracy of individual isoforms in >80% of cases by a median of ~1.8-2.4-fold improvement 97 and of total gene expression by 25-70%. In parallel, our isoform-centric framework uncovers cross-98 99 validated predictive models for ~2-fold more genes, doubling the number of testable features in the trait 100 mapping step. Third, divergent patterns of genetic effects across isoforms can be leveraged to provide a 101 more granular hypothesis for a mechanism underlying the SNP-trait relationship. Finally, the isoTWAS 102 framework jointly captures expression and splicing disease mechanisms, while maintaining a wellcontrolled false discovery rate. Altogether, using GWAS data for 15 neuropsychiatric traits, isoTWAS 103 greatly increases the power to detect gene-level trait associations uncovering associations at ~60% more 104 GWAS loci compared to traditional gene-level TWAS. These results stress the need to shift focus to 105 106 transcript-isoforms to increase discovery of transcriptomic mechanisms underlying genetic associations 107 with complex traits.

108

109 **RESULTS**

110 The isoTWAS framework

isoTWAS seeks to prioritize genes with transcript-isoforms of genes whose *cis*-genetic component of
 expression is significantly associated with a complex trait. We extend the traditional gene-level TWAS

113 approach by jointly modeling the expression of distinct transcript-isoforms of a given gene as a matrix 114 while accounting for the pair-wise correlations between these isoforms^{21,37,39,40}. Here, we assume that 115 local genetic variants directly modulate expression of an isoform. In addition, we assume that the 116 abundance of a gene is measured as the is the sum of the abundance of its isoforms, computed as transcripts per million, or TPM (Supplemental Figure S1)^{32,33,41,42}. Flexibly integrating isoform-level 117 expression into trait mapping may lead to novel discoveries in disease mapping and prioritize specific 118 isoforms that explain genetic associations. Accordingly, gene-level trait mapping using traditional TWAS 119 120 methods may not necessarily detect a trait association on the gene-level if a gene has multiple isoforms 121 but only one is associated with the trait (Figure 1a). This scenario may be particularly relevant in the 122 human brain, where some genes may express up to hundreds to thousands of unique isoforms²⁵. By modeling the genetic architectures of isoforms of a gene simultaneously, isoTWAS provides a deeper 123 124 understanding of potential transcriptomic mechanisms that underlie genetic associations.

125

The isoTWAS framework contains three general steps (Figure 1). First, we build multivariate predictive 126 127 models of isoform-level expression using well-powered functional genomics training datasets, including GTEx³⁷ and PsychENCODE^{24,27}. Here, we trained and systematically compared 4 multivariate predictive 128 129 frameworks: (1) multivariate elastic net penalized regression⁴³, (2) multivariate LASSO penalized regression with simultaneous covariance estimation (MRCE)⁴⁴, (3) multivariate elastic net regression with 130 stacked generalization (joinet)⁴⁵, and (4) sparse partial least squares (SPLS)⁴⁶. As a baseline for 131 comparison, we also modeled each individual isoform independently with univariate regularized 132 regressions, as implemented in Gusev et al's FUSION software^{4,43,47,48} (see Methods and Supplemental 133 Methods). Models were trained to predict isoform expression using the set of *cis*-SNPs within 1 134 Megabase (Mb) of the gene body (Methods, Figure 1b). Model performance was assessed via 5-fold 135 cross-validation, using McNemar's adjusted R² between observed and predicted expression. 136 137

Next, we use these models to impute isoform expression into an external GWAS cohort and quantify the
association with the target GWAS phenotype (Figure 1b). If individual-level genotypes are available,
isoform expression can be directly imputed as a linear combination of the SNPs in the models, and these

141 associations can be estimated through appropriate regression analyses. If only GWAS summary statistics 142 are available, imputation and association testing is conducted simultaneously through a weighted burden 143 test⁴. Finally, isoTWAS performs step-wise hypothesis testing procedure to account for multiple 144 comparisons and control for local LD structure. Isoform-level P-value are first aggregated to the genelevel to prioritize a gene using the Aggregated Cauchy Association Test (ACAT)⁴⁹, where false discovery 145 rates are controlled, and then individual isoforms of prioritized genes are subjected to post-hoc family-146 wise error control⁵⁰ (Supplemental Figure S2, Methods). After this step, a set of isoforms are identified 147 148 whose *cis*-genetic component of expression are associated with the trait of interest⁴. For these isoforms, 149 we apply a rigorous permutation test whereby the SNP-to-isoform effects are permuted 10,000 times to generate a null distribution; this permutation test assesses how much signal is added by isoform 150 expression, given the GWAS architecture of the locus, and controls for large LD blocks⁴. Lastly, we can 151 isoform-level Bayesian fine-mapping at each locus with a significant trait association to identify the 152 minimal credible set of isoforms that contains the 'casual' isoform at a 90% confidence level and to assign 153 individual posterior inclusion probabilities (Figure 1b, Methods). isoTWAS is available as an R package 154 through Github (https://github.com/bhattacharya-a-bt/isotwas). 155

156

157 isoTWAS improves prediction of isoform and gene expression in simulations and real data

Previous work has demonstrated that isoform-level quantifications, when propagated to the gene-level, 158 can lead to more accurate gene expression estimates and differential expression results with short read 159 RNA-seq data^{41,42}. We therefore hypothesized that our multivariate SNP-based imputation of isoform 160 expression, when summed to the gene-level, would outperform traditional gene-level TWAS models. To 161 systematically evaluate the performance of TWAS versus isoTWAS models on prediction of total gene 162 163 expression across a variety of genetic architectures, we conducted an extensive set of simulations across 22 different gene loci using European-ancestry data from the 1000 Genomes Project⁵¹ (Methods, Figure 164 2a). At each gene locus, we controlled gene expression heritability and simulated 2-10 distinct isoforms, 165 166 varying the proportion of causal isoQTLs (p_{causal}) and their sharing between isoforms (p_{shared}). We then trained cross-validated, multivariate predictive models of isoform expression (isoTWAS) or univariate 167 models of gene expression (TWAS). For isoTWAS, of the specific multivariate prediction models tested, 168

multivariate elastic net⁴³ demonstrated the greatest CV prediction of isoform expression across most 169 170 simulation settings (Figure 2b, Supplemental Figure S3, Supplemental Data 1). For gene expression 171 prediction, the optimal isoTWAS models (in sum) outperformed the optimal TWAS model, particularly at 172 sparser isoQTL architectures, with median absolute increase in adjusted R² of 0.6-3.5% (Figure 2c, Supplemental Figure S4, Supplemental Data 2). Performance gains decreased somewhat with denser 173 174 isoQTL architectures, although real data is consistent with 0.1-1% sparsity (i.e., 1-10 causal e- and isoQTLs per gene or isoform)³⁷. In simulations, we found that isoTWAS prediction of gene expression 175 176 also increases as the proportion of shared non-zero effect SNPs across isoforms decreases (Figure 2b-177 c, Supplemental Figure S4, Supplemental Data 2).

178

Next, we assessed predictive performance in real data from 48 tissues (13 brain) with sufficient sample 179 sizes (N > 100) in GTEx for all genes with multiple expressed isoforms (Supplemental Table S1; 180 Methods). Altogether, for 48 tissues in GTEx, we built significant predictive models for 50,000 to 80,000 181 isoforms across 8,000 to 12,000 unique genes per tissue (Supplemental Figure S11, Supplemental 182 Table S2). We considered 3 main criteria to evaluate the performance of both the multivariate and 183 isoform-centric approaches of isoTWAS: (1) the number of isoforms whose expression can be imputed 184 185 using multivariate/univariate models with cross-validation (CV) $R^2 > 0.01$; (2) the number of unique genes with at least one isoform that can be imputed at CV $R^2 > 0.01$; and (3) the number of unique genes in 186 which total gene expression can be imputed at CV $R^2 > 0.01$ using isoTWAS (summed) or TWAS models. 187 188

At the isoform level (criterion 1), through joint multivariate modeling of isoform expression, we trained 2.3-189 2.5-fold more models at cross-validation (CV) R² > 0.01 across the 48 tissues, compared to traditional 190 univariate approaches (Figure 3a, Supplemental Figure S5). Using these multivariate models, we 191 192 improve prediction for 79-82% of isoforms with a median increase of ~1.8-2.4 fold increase in adjusted R² 193 (Supplemental Figure S6, Supplemental Table S2). Concordant with simulations, we found that the 194 multivariate elastic net overwhelmingly outperformed other multivariate (and univariate) methods, indicating that leveraging the shared genetic architecture between isoforms of the same gene greatly aids 195 in prediction of each individual isoform (Supplemental Figure S7, Supplemental Table S2). Notably, we 196

observed that multivariate models were particularly important for brain tissues compared with non-brain tissues in GTEx, which showed significantly improved performance compared with univariate models (**Figure 3b**; P = 0.011 from OLS regression of median percent increase in CV R² for multivariate/univariate models against tissue type, adjusted for sample size), suggesting more shared isoQTL architecture in brain tissues than others which can be leveraged by isoTWAS for improved prediction. These gains in prediction accuracy directly translate into increased power in the trait association step⁵².

204

205 At the gene level (criteria 2 and 3), isoTWAS also increased the number of genes with testable models in 206 the trait mapping step and improved prediction of total gene expression. The number of unique genes with at least 1 isoTWAS model at CV R² > 0.01 (inclusion criterion for isoTWAS trait mapping) was 1.9-207 2.5 times larger than the number of unique genes with TWAS models achieving CV R² > 0.01 for gene 208 expression prediction (Figure 3c, Supplemental Figure S8, Supplemental Table S2). For a given gene, 209 isoTWAS models (summed) outperformed TWAS models in prediction of total gene expression by a 210 median of 25-70% in cross validation (Supplemental Figure S9) with a 50-80% increase in the number 211 of genes that are predicted at CV R² > 0.01 (Figure 3d, Supplemental Figure S10). We replicated these 212 213 gains in total gene expression prediction using an independent, out of sample QTL reference panel of 214 adult cortex from PsychENCODE/AMP-AD (Methods). Multivariate isoTWAS models outperformed univariate TWAS models in predicting total gene expression with a 15.2% median percent increase in 215 adjusted R² when training in GTEx and testing in PsychENCODE/AMP-AD, and 23.9% vice versa; Figure 216 3e, Supplemental Table S3). As predictive performance is positively related to power to detect trait 217 associations⁵¹, both the increased number and accuracy of trainable imputation models using isoTWAS's 218 multivariate predictive framework have strong implications on increased discovery in trait mapping⁵¹. 219 220

221 Performance of isoTWAS across distinct genomic contexts

As genes can differ widely with respect to the number and expression patterns of their constituent isoforms, as well as by other potentially relevant features such as gene length and SNP density, we next sought to characterize the impact of these factors of isoTWAS performance using GTEx models as

evaluated by the 3 criteria outlined above (Methods, Supplemental Note, Supplemental Figures S12-225 226 19, Supplemental Data 3-4). Overall, we observed an increase in performance of isoTWAS multivariate 227 modeling of both isoforms and genes with increasing number of isoforms per gene, although there was less conclusive of a pattern with increasing dominant isoform fraction⁵² (Supplemental Figures S12-13, 228 Supplemental Note, Methods). We also noticed trends in the performance gain using isoTWAS 229 multivariate modeling with respect to both isoform and gene expression prediction across gene length, 230 SNP density at the gene locus, and sample size (Supplemental Figures S14-16, Supplemental Note). 231 232 Finally, as the proportion of non-zero effect SNPs in the isoTWAS model that are shared across isoforms 233 increased (Supplemental Note), we found an increasing trend in the gain in prediction of gene 234 expression using isoTWAS compared to TWAS models (Supplemental Figure S17), reflecting a similar observation from simulation. Interestingly, as this proportion increased, we found an increase in the gain 235 in prediction of isoform expression, reinforcing the utility of multivariate modelling in marginal prediction of 236 isoform expression. 237

238

239 Lastly, we investigated how the robustness of isoform abundance estimation from short-read RNA-seq 240 impacted performance gains of isoTWAS, compared with TWAS. Isoform abundance was initially 241 quantified from probabilistic point estimates using Salmon, guided by Gencode annotations. We then 242 assessed the performance of isoTWAS across loci binned by quantification variance measured across 50 inferential replicates from Salmon³². In general, we found that for isoform-level prediction, multivariate 243 modeling in isoTWAS substantially outperformed univariate approaches as quantification variance 244 increased. However, comparing isoTWAS isoform-centric and TWAS gene-centric models, there were no 245 246 discernable trends in prediction of gene expression as the mean count and/or quantification variance of 247 genes increased (Supplemental Figure S18-19, Supplemental Note). Finally, we evaluated the impact of reference transcriptome annotation fidelity by generating a synthetic dataset quantified using a 248 reference annotation masking the dominant isoforms for a set of genes. As expected, performance of 249 250 both isoTWAS and TWAS models declined when isoforms failed to be detected in expression quantification (Supplemental Note, Supplemental Figure S20). 251

252

253 Simulations support improved power and calibrated null across genetic architectures

254 We next introduced GWAS data for complex traits into our simulation framework to benchmark the false 255 positive rate (FPR) and power of isoTWAS (Methods). First, we found that the FPR is controlled at 0.05 256 for isoform-level mapping using ACAT, consistent with gene-level mapping using TWAS (Supplemental Figure S21, Supplemental Data 4). For a simulated trait, we modeled causal effect architectures for a 257 genomic locus with 2-10 isoforms under three main scenarios (Methods; Figure 4, Supplemental Figure 258 259 **S22**); (1) where the true trait effect is from only total gene expression, (2) where there is only one isoform 260 with a non-zero effect on the trait, called the "effect isoform"; and (3) where 2 isoforms are effect isoforms, 261 with varying magnitudes and directions of association. This first scenario showed clear increases in power for TWAS over isoTWAS, but this advantage declined as the causal proportion of isoQTLs 262 increased and as the proportion of shared isoQTLs increased (Figure 4a, Supplemental Data 5). For 263 scenarios (2) and (3), as effects on the trait varied across isoforms of the same gene (Figure 4b-c, 264 Supplemental Data 6-7), we observed large increases in power for isoTWAS over TWAS. Here, across 265 most scenarios and causal effect architectures, isoTWAS demonstrated improved power compared with 266 267 gene-level TWAS, particularly when only one isoform of a gene carried a trait effect or when two effect 268 isoforms of the same gene had different directions of effects. However, when the effect sizes of two effect 269 isoforms of the same gene converged, TWAS and isoTWAS demonstrated similar power to detect a gene-trait association (Figure 4c). 270

271

Finally, we assessed the performance of probabilistic fine-mapping in identifying the true effect isoform in our simulation framework of genes with 5 or 10 isoforms (**Methods**, **Supplemental Figure S23**,

Supplemental Data 9). In general, the sensitivity of 90% credible sets (proportion of credible sets that contained the true effect isoform) was under-calibrated, likely due to difficulties in fine-mapping when QTL horizontal pleiotropy is extremely high⁵³. We found that the sensitivity of 90% credible sets decreased and the mean set size increased with increasing proportion of shared isoQTLs. Our simulation results suggest that varied isoQTL architectures and isoform-trait effects for isoforms of the same gene are key features that influence power gains in isoform-centric modeling.

280

281 isoTWAS increases discovery of trait associations across 15 neuropsychiatric disorders

282 To explore our central hypothesis that isoform-centric multivariate predictive modeling will improve 283 discovery for complex trait mapping, particularly for brain relevant traits, we next sought to apply and 284 directly compare isoTWAS and TWAS results across 15 neuropsychiatric disorders and traits. To maximize discovery, we trained both isoTWAS and TWAS models using a greatly expanded adult brain 285 functional genomics reference panel (N = 2,115), comprised of frontal cortex samples from 286 PsychENCODE and AMP-AD Consortia^{27,54}, as well as using a developmental⁵⁵ pre-frontal cortex (N = 287 288 205) dataset (Methods; Figure 5). In the adult cortex, we trained models for 15,127 genes using 289 isoTWAS passing the CV R² > 0.01 cutoff, compared with 14,283 genes using gene-level TWAS. In the 290 developing cortex, despite a smaller sample size, isoTWAS models were successfully trained for 16,504 genes, compared with 10,535 genes using TWAS (Methods; Supplemental Table S1). 291 292 We next applied these models to perform trait associations using summary statistics from 15 293

neuropsychiatric and brain-related GWAS⁵⁶⁻⁷⁰ (Methods, Figure 5a, Supplemental Figure S24), using 294 the conservative stepwise hypothesis testing procedure (Figure 1a; FDR-adjusted P < 0.05 and within-295 296 locus permutation PACAT < 0.05). We detected far more trait-associated genes with isoTWAS compared 297 with TWAS, across adult (2,595 vs 1,589 genes) and developmental (4,062 vs 890 genes) reference panels, respectively (Supplemental Figure S25, Supplemental Data 10-13). In total across both 298 reference panels and all 15 traits, isoTWAS detected 3,436 unique gene and 5,377 unique isoform-trait 299 associations (Supplemental Figure S26). In addition, of the 1,335 genes with multiple isoform-trait 300 associations, 661 gene exhibited distinct isoform-level associations in different directions. 301

302

We next sought to compare the performance of isoTWAS/TWAS in prioritizing candidate mechanisms within independent, high-confidence GWAS-significant loci⁷³. Across a combined 1,149 GWAS loci, isoTWAS identified significant associations within 323, compared with 201 detected by TWAS, a ~60% increase in discovery (**Figure 5b**; **Methods, Supplemental Table S4**). For example, of the 287 GWAS loci identified for SCZ⁷⁴, isoTWAS prioritized genes within 70 and 86 unique loci across adult and developmental reference panels, respectively, compared with 56 and 29 loci for TWAS (**Figure 5b**).

309 Further, across the 15 traits, 96% of gene-level TWAS associations (193/201) were concordantly 310 identified by isoTWAS. Likewise, the standardized effect sizes for significant gene- and isoform-level associations were highly correlated (r = 0.84, P < 2.2×10^{-16} ; Figure 5c). Finally, to explore whether these 311 isoTWAS-specific associations were capturing true disease signal, we compared the rate at which each 312 method prioritized constrained genes (probability of loss-of-function intolerance, pLI \ge 0.9; Supplemental 313 Tables S5-S8), which are known to be substantially enriched for disease associations⁷⁵. Across adult and 314 developmental panels for 15 traits, respectively, isoTWAS prioritized 724 and 385 constrained genes 315 316 compared with 106 and 200 with TWAS, a significant increase (adult: P=0.048, developmental: P = 1.23 x 10⁻⁵, Fisher's Exact test). Altogether, these results emphasize that isoTWAS not only recovers the vast 317 majority of TWAS associations but also greatly increases discovery of candidate GWAS mechanisms, 318 319 particularly for genes intolerant to protein-truncating variation⁷⁶. 320

321 In our evaluation of methods in real data, we sought to compare discovery using isoTWAS to discovery 322 using local splicing-event based trait mapping. Briefly, for the developmental brain dataset, we first calculated intron usage using Leafcutter⁷⁷ and transformed these usage percentages to M-values⁷⁸. Then, 323 for all introns mapped to a given gene, we used all SNPs within 1 Mb of a splicing-event to predict its 324 usage and mapped trait associations for these splicing events using isoTWAS's multivariate framework 325 326 (Methods). Overall, when aggregated to the gene-level, across 15 traits, we found that isoTWAS 327 prioritized features at ~40% more independent GWAS loci (167 loci) than splicing-event based trait 328 mapping (119 loci), with 108 loci (90.7%) jointly identified (Figure 5f), using the same developmental 329 brain reference panel. Taken together, isoTWAS's specific focus on modeling isoforms of a gene provided considerable gains over considering only total gene expression or intron usage in identifying trait 330 associations for genes and their transcript-isoforms. 331

332

To investigate whether this increase in trait mapping discovery reflected true biological signal, rather than test statistic inflation due to the increased number of tests (~4-fold increase in number of tests), we next compared the null distributions across methods for results across the 15 traits (**Supplemental Figure S27).** As the genomic inflation factor is not a reliable measure in TWAS settings⁷⁹, we estimated inflation

in gene-level test statistics using an empirical Bayes approach (Methods). Collapsing across all 15 traits,
there were no significant differences between TWAS and isoTWAS in the 95% credible intervals for test
statistic inflation (Figure 5d). Using a heuristic to estimate increases in effective sample size (Methods),
we observed an approximate increase in effective sample size of 10-20% when using isoTWAS
compared to TWAS (Figure 5e, Supplemental Table S9). These analyses indicate that isoTWAS
discovery is both well-calibrated to the null and facilitates increased discovery in real data compared to
gene-level TWAS.

344

345 We also empirically compared probabilistic fine-mapping⁵⁵ of results from isoTWAS and gene-level TWAS 346 (Methods). Here, we conducted fine-mapping on significant trait-associated genes/isoforms (adjusted P < 0.05 and permutation P < 0.05) and are within 1 Mb of one another; we term a locus with overlapping 347 genes/isoforms a risk region. Overall, the mean number of genes in a risk region using TWAS was 3.15 348 compared to 3.90 using isoTWAS (Supplemental Figure 28a); the mean number of genes in a 90% 349 credible set using TWAS was 1.33 compared to 1.25 using isoTWAS (Supplemental Figure 28a). On 350 average, there were 1.54 isoforms per gene in a risk region and 1.27 isoforms per gene in a 90% credible 351 352 set (Supplemental Figure 28b). Isoform-centric modeling presents unique challenges for fine-mapping 353 due to potentially high levels of horizontal pleiotropy, and remains an important and open question for the 354 field. Nevertheless, isoTWAS identified a relatively comparable number of genes in risk regions compared 355 with TWAS, and the combination of conservative two-step trait mapping, permutation testing, and probabilistic fine-mapping were critical for maintaining a narrow credible set size. 356

357

358 isoTWAS identifies biologically-meaningful trait associations undetectable by TWAS

Overall, isoTWAS prioritized dozens of novel candidate risk genes and mechanisms in the developing and adult brain for 15 neuropsychiatric traits. These isoTWAS-prioritized genes were enriched for multiple relevant pathways consistent with the biology of the underlying trait, including cell proliferation pathways for brain volume, calcium channel activity for schizophrenia and neuroticism, and proteasome regulation in Alzheimer's Disease, among others (**Supplemental Figure S29**). We highlight below several examples of novel trait associations in which isoTWAS prioritized a highly constrained gene within a

365 GWAS locus (Supplemental Table S5-8). For example, we identified an association for SCZ with 366 developmental expression of ENST00000519133, an isoform of SNAP91 (adjusted P = 6.06×10^{-7} in 367 isoTWAS, pLI = 0.99, chromosomal location of 6q14.2), with a GWAS-significant variant rs217291 within 368 the gene body. SNAP91 has been predicted to affect clathrin and phosphatidylinositol biding activity and synaptic vesicle recycling and has previously shown to impact synaptic development⁸⁰. In addition, we 369 370 found that imputed developmental cortex expression of ENST00000476671, an isoform of KMT2E, was associated with CDG risk (adjusted P = 7.63×10^{-3} , pLI = 1, chromosomal location of 7q22.3): the GWAS 371 SNP rs2385537, associated in a meta-analysis of ADHD, ASD, BP, and SCZ⁸¹, is within the gene body. 372 373 KMT2E regulates post-translational histone methylation of histone 3 on lysine 4A, and KMT2E 374 heterozygous variants are associated with risk of neurodevelopmental disorders⁸². Imputed adult brain expression of ENST00000492146 (adjusted P = 1.14×10^{-6} , pLI = 0.94, chromosomal location of 3p21.1), 375 an isoform of SFMBT1, showed a strong association with SCZ risk and contains a GWAS SNP within the 376 gene body (rs2071044). In a recent gene-based analysis of GWAS data for SCZ and BD, decreased 377 expression of SFMBT1 was associated with increased risk of both disorders⁸³, consistent with the effects 378 for the isoform we identify in this isoTWAS analysis. Lastly, our analysis implicated ENST00000537270, 379 380 an isoform of KMT5A (pLI = 0.99, found in 12q24.31), in an association with SCZ risk. KMT5A, a H4K20 381 methyltransferase, has been previously implicated in GWAS for SCZ but cis-eQTLs of the gene have not be colocalized with the GWAS signal previously^{74,84,85}. 382

383

As evidenced by our simulation analyses, a main advantage of isoTWAS over TWAS is the identification 384 385 of trait associations for isoforms of genes, where the gene itself is not associated with the trait. We illustrate several examples of isoforms prioritized by isoTWAS, all in adult cortex, for genes with limited or 386 387 distinct expression QTLs (Figure 6, Supplemental Figure S30, Supplemental Data 14). First, we detected a strong SCZ association with ENST00000492957, an isoform of AKT3 (pLI = 1) at 1q43-q44, 388 which encodes a serine/threonine-protein kinase that regulated many processes like metabolism and cell 389 390 growth, proliferation, and survival. AKT3 has shown effects on anxiety, spatial and contextual memory, and fear extinction in mice, such that loss-of-function of AKT3 causes learning and memory deficits^{86,87}. 391 Within the GWAS locus, there was a strong overlapping isoQTL signal ($P < 10^{-50}$); however, the eQTL 392

signal includes only a single SNP that reaches $P < 10^{-6}$, which is in low LD with the GWAS-significant 393 394 SNPs in the locus (Figure 6a). The lead isoQTL (rs4430311) showed a significant, negative association 395 with ENST00000492957, but not AKT3 expression, with increasing SCZ risk alleles. However, this SNP 396 has only a nominally significant positive association with AKT3, as the number of alternative alleles at the SNP increased. Interestingly, a different isoform of AKT3 (ENST00000681794) was prioritized in an 397 association with BV, which also has a GWAS hit at this locus (Supplemental Figure S30). The two 398 distinct isoforms of AKT3 have distinct 3' transcript structures, particularly close to the lead isoQTL of 399 400 ENST00000681794. These results suggest a complex role of AKT3 isoforms with brain-related traits to be 401 explored further computationally and experimentally.

402

Similarly, we found a strong isoQTL signal for ENST00000409096 but a weak eQTL signal of CUL3 in the 403 404 2q36.2 locus (pLI = 0.99), in another association with SCZ (Figure 6b). CUL3 is a component of Cullin-RING E3 ubiquitin ligase complexes, involved in protein ubiquitylation, cell cycle regulation, protein 405 trafficking, signal transduction, and transcription. Previous work has implicated CUL3 dysregulation as a 406 pathological mechanism for both SCZ and ASD risk⁸⁸. Next, an isoform ENST00000678969 of HSPD1, 407 encoding a mitochondrial heat shock protein, was associated with SCZ risk (adjusted P = 8.79×10^{-12} , pLI 408 409 = 0.99, 2q33.1) and showed a similar pattern across GWAS, eQTL, and isoQTL signals (Figure 6c). HSPD1 was identified in 3 independent secondary analyses of SCZ GWAS data, is among multiple non-410 MHC immune genes implicated in SCZ, and has roles in brain hypomyelination⁸⁹. Our work adds to these 411 previous studies by implicating a specific isoform of HSPD1 at the locus. Lastly, ENST00000423517, an 412 isoform of PCLO, was associated with multiple traits in the CDG analysis (meta-analysis of ADHD, BP, 413 MDD, and SCZ; adjusted $P = 1.83 \times 10^{-4}$, pLI = 1). Again, we found a strong isoQTL but not eQTL signal, 414 415 with the CDG risk allele negatively associated with isoform expression. PCLO is involved in the presynaptic cytoskeletal matrix, establishing active synaptic zones, and synaptic vesicle trafficking; rare 416 variants of PCLO in diverse populations have been recently implicated in risk of SCZ and ASD^{90,91}. 417 418 Altogether, these results highlight the importance of incorporating isoform-level regulation for prioritizing novel candidate GWAS risk mechanisms, as implemented in our isoTWAS framework. 419

420

421 DISCUSSION

In this work, we introduce isoTWAS, a scalable framework that integrates genetic and isoform-level transcriptomic variation with GWAS to not only identify genes whose expression are associated with a trait but also prioritize a set of isoforms of the gene that best explains the association. We provide an extensive set of isoform-level predictive models (<u>https://zenodo.org/record/6795947</u>⁹²) and software to conduct isoform-level trait mapping with GWAS summary statistics (<u>https://github.com/bhattacharya-a-</u> bt/isoTWAS).

428

429 As demonstrated above, isoTWAS presents several advantages over traditional gene-level TWAS or 430 simple univariate modeling of isoform expression. First, modeling expression at the isoform-level can detect isoQTL architectures that vary across isoforms and thus may not be captured by eQTLs of a gene. 431 Second, joint multivariate isoform-level modeling improved predictive accuracy of isoform and total gene 432 expression, both in simulated and real data with independent replication. Third, aggregating isoform-level 433 434 associations to the gene-level through ACAT substantially increased power to detect trait associations over traditional TWAS. We attribute this increase in power to several key features: first, isoform-level 435 436 modeling in isoTWAS increases the number of imputable genes by >2-fold; second, isoTWAS models 437 improve accuracy of gene-level prediction by as much as 35%; third, isoTWAS jointly models both 438 expression and splicing regulation, thereby capturing multiple potential underlying complex trait mechanisms. Finally, as genetic control of isoform expression and usage are often much more tissue-439 and cell-type-specific than eQTLs^{26,37}, we hypothesize that isoTWAS is more capable of uncovering such 440 context-specific trait associations. 441

442

Recent work has highlighted the promise of alternative splicing as a biological mechanism underlying complex traits not fully captured through eQTLs^{24,26,27,93}. Splicing-QTL integration is a promising vehicle to prioritize alternative exons or splice sites that may explain the genetic association with a trait, but a single exon or splice site can correspond to multiple isoforms of the same gene. Mapping genetic regulation at the exon- rather than gene-level often leads to more detected signal⁹⁴. However, most of these analyses have focused on local splicing events or exon-level inclusion, rather than the combined

449 consequences of these events - namely, different isoforms of the same gene. Local splicing events can 450 be computationally intensive to measure and are difficult to systematically integrate across multiple 451 distinct large-scale datasets, which is necessary for achieving sample sizes sufficient for interrogation of population-level allelic effects^{27,28}. Furthermore, multiple splicing changes are often coordinated across a 452 gene, yielding many non-independent features that increase multiple testing burden. Our results 453 demonstrate that isoform-centric trait mapping with isoTWAS increases discovery by ~40% compared 454 with a matched local splicing event-based analysis, although these methods may recover some 455 456 independent signal. Future work should consider integrating both reference-guided and annotation-free 457 approaches for quantification and detection of isoform and splicing patterns to develop more nuanced mechanistic hypotheses for GWAS loci. 458

459

We conclude with some limitations of and future considerations for isoTWAS. First, we note that isoform-460 level expression quantifications are maximum-likelihood estimates, due to the inherent limitations of 461 462 short-read RNA-seq. These estimates are generally guided by existing transcriptome annotations (e.g., 463 GENCODE) and thus are dependent on the completeness and accuracy of these genomic annotations. 464 Further, many dataset-specific sequencing factors may will affect the accuracy of these estimates, 465 especially sequencing depth, read length and library preparation (mRNA vs total RNA sequencing). The continued emergence of long-read sequencing platforms, including PacBio IsoSeg and Oxford Nanopore 466 Technologies, will be instrumental for improving reference transcriptome annotations, particularly with 467 tissue specificity, which will in turn improve isoTWAS. Further, as these methods continue to gain 468 scalability and cost effectiveness, they will ultimately replace short-read sequencing (and isoform 469 estimation) for population-scale datasets. As isoTWAS is agnostic to the method of isoform expression 470 471 quantification, this framework will continue to be applicable as we approach this long read sequencing era. Recent analyses have shown that larger sample sizes may outweigh sequencing coverage for eQTL 472 mapping, but this relationship has not been investigated for isoform-level expression⁹⁵. Thus, for optimal 473 474 discovery with isoTWAS, the appropriate balance between sample size and reference panel sequencing depth remains to be determined. 475

476

477 Second, while inferential replicates from RNA-seq quantification can provide measures of technical 478 variation, they are not incorporated into the predictive models. Our analyses of prediction across 479 inferential replicates suggest a methodological opportunity: leveraging these inferential replicates as a 480 measure of quantification error may help in estimating the robustness of isoform prediction and, potentially, of the precision of these SNP effects. A more flexible predictive model that estimates standard 481 errors for SNP effects by model-averaging across the replicate datasets may help with trait mapping by 482 483 providing a prediction interval for both isoform- and gene-level imputed expression. Third, just as TWAS 484 can be cast as a differential gene expression analysis conducted with imputed expression, isoform-level 485 trait mapping is akin to differential transcript expression analysis. An analogous goal of isoTWAS can be 486 to detect trait associations with genetically-regulated transcript usage. However, it is unclear if the compositional nature of transcript usage data needs to accounted for at the prediction step or the trait 487 mapping steps⁹⁶. Lastly, as we show, this framework can suffer from reduced power, inflated false 488 positives, and reduced sensitivity in fine-mapping in the presence of SNP horizontal pleiotropy, where the 489 490 genetic variants in the isoform expression model affect the trait, independent of isoform expression, or when multiple SNPs affect expression of isoforms^{97,98}. For pathways that are not observed or accounted 491 492 for in the reference expression panel and GWAS, accounting for horizontal pleiotropy may improve trait 493 mapping. We motivate further methodological extensions of probabilistic fine-mapping to reconcile 494 pleiotropy for SNPs shared across models for multiple isoforms at the same genetic locus, as summarystatistic based methods that control for horizontal pleiotropy are not yet effective⁹⁹. 495

496

In sum, isoTWAS provides a novel framework to scalably interrogate the transcriptomic mechanisms
underlying genetic associations with complex traits and generate biologically-meaningful and testable
hypotheses about disease risk mechanisms. Based on our results, we emphasize a shift in focus from
quantifications of the transcriptome on the gene-level to the transcript-isoform level to maximize discovery
of transcriptome-centric genetic associations with complex traits.

502

503 METHODS

504 isoTWAS consists of three steps: (1) training predictive models of isoform expression, (2) imputing

505 isoform-specific expression into a separate GWAS panel, and (3) association testing between imputed

506 expression and a phenotype (Figure 1b). isoTWAS contrasts with TWAS as it models correlations

507 between the expression of isoforms of the same gene. We outline each step below, with further

- 508 mathematical details in **Supplemental Methods**.
- 509

510 Training predictive models of isoform expression

511 Model and assumptions

512 Assume a given gene *G* has *M* isoforms with expression levels across *N* samples, with each sample

having *R* inferential replicates. Let Y_G^* be the $N \times M$ matrix of mean isoform expression (log-scale TPM) for

the *N* samples and *M* isoforms, using the point estimates from the Expectation-Maximization algorithm of

a pseudo-mapping quantification algorithm, like Salmon or kallisto^{32,33}. We can jointly model isoform

516 expression with a system of $N \times M \times R$ equations. For sample $n \in \{1, ..., N\}$, isoform $m \in \{1, ..., M\}$ of gene

- 517 *G*, and replicate $r \in \{1, ..., R\}$, we have:
- 518 $y_{nmr} = x_n \beta_m + \epsilon_{nmr} \quad (1),$

where y_{nmr} is the expression of isoform m for the rth inferential replicate of sample n, x_n is the P-vector 519 (vector of length P) of cis-genotypes in a 1 Mb window around gene G, β_m is the P-vector of genetic 520 effects of the P genotypes on isoform expression, and ϵ_{nmr} is normally distributed random noise with 521 mean 0 and variance σ_{nmr}^2 . We standardize both the genotypes and the isoform expression to mean 0 522 and variance 1. As the SNP vector x_n does not differ across inferential replicates, we impose the following 523 assumptions on the variance-covariance matrix of $\epsilon = (\epsilon_{1,1,1}, \epsilon_{1,1,2}, \dots, \epsilon_{nmr})^T$, the vector of random errors: 524 525 we assume that ϵ_{nmr} are independent and identically distributed across samples $n \in \{1, ..., N\}$ and identically distributed across replicates $r \in \{1, ..., R\}$. Accordingly, the point estimates of the SNP effects 526 527 on isoform expression are not influenced by differences in expression across replications. Therefore, in matrix form, we consider the following predictive model: 528

529 $Y_G^* = X_G B_G + E_G \quad (2)$

Here, X_G is the $N \times P$ matrix of genotype dosages, B_G is the $P \times M$ matrix of SNP effects on isoform expression and E_G is a matrix of random errors, such that $vec(E_G) \sim N_{NM}(0, \Sigma = \Omega^{-1} \otimes I_N)$. Σ represents

the variance-covariance matrix in the errors (with precision matrix $\Omega = \Sigma^{-1}$), following the aforementioned independence assumptions.

534

535 Estimating SNP effects on isoform expression

536 We apply 5 different methods to estimate \hat{B}_{g} , the matrix of SNP effects on isoform expression. The first 537 four are multivariate methods that model the isoforms jointly; the last method models each isoform

538 separately using univariate methods. The goal of this SNP effect estimation is marginal prediction, i.e.,

leveraging the correlation between isoforms to improve prediction of each isoform separately. The \hat{B}_{G}

540 matrix that gives the largest adjusted R² in 5-fold cross-validation across the 5 methods is selected as the

final model to predict isoform expression for a given gene. In settings where we are interested in

542 predicting gene-level expression from these predicted isoforms, isoTWAS trains an elastic net penalized

543 linear regression that predicts gene-level expression from genetically-predicted isoform-level expression;

this model training is conducted across the same 5 folds to prevent data leakage¹⁰⁰. We provide an

545 overview of the methods, with mathematical details in **Supplemental Methods**:

Multivariate elastic net (MVEnet) regression: This is an extension of elastic net, where the response is
 a matrix of correlated responses⁴³. Here, the absolute penalty is imposed on each single coefficient

by a group-lasso penalty on each vector of SNP effects across isoforms (rows of B_G); accordingly, a

549 SNP can only have a non-zero effect on an isoform if it has a non-zero effect on all isoforms.

550 2. Multivariate LASSO Regression with covariance estimation (MRCE): We adapt Rothman et al's

proposed procedure to simultaneously and iteratively estimate both \hat{B}_{G} , the SNP effects matrix, and $\hat{\Omega}$, the precision matrix⁴⁴. This procedure accounts for the correlation between isoforms but does not

impose the group-lasso penalty as in MVEnet. As such, a single SNP need not have a non-zero effecton all isoforms.

Multivariate elastic net with stacked generalization (joinet): We use Rauschenberger and Glaab's
 joinet method that uses a two-step prediction⁴⁵. In the first step, the design matrix of SNPs is used to
 generate a cross-validated prediction of each isoform. In the second step, the matrix of predicted
 isoform expression is used to predict each isoform.

Sparse partial least squares (SPLS): This is an implementation of partial least squares with a sparsity
 penalty, that attempts to find an optimal latent decomposition for the linear relationship between the
 matrix of isoform expression and the design matrix of SNPs. We use the Chun and Keles's
 implementation from the spls R package⁴⁶.

563 5. Univariate FUSION: the simplest implemented method is the univariate predictive modelling used in

564 FUSION². We disregard the correlation structure between isoforms and train a univariate elastic net⁴³,

565 estimation of the best linear unbiased predictor (BLUP) in a linear mixed model¹⁰¹, and SuSiE⁴⁷

predictive model for each isoform separately. The model with the largest adjusted R² out of these

567 three models is outputted. This approach serves as a baseline measurement for prediction of each

568 isoform independently.

569

570 Trait association and step-wise hypothesis testing

We note that the tests of association in isoTWAS are similar to tests in differential transcript expression 571 analyses, as TWAS tests of association are analogous to tests in differential gene expression analyses. 572 573 isoTWAS and TWAS are distinct, as these methods consider imputed isoform and gene expression, 574 respectively, as predicted by the trained expression models. If individual-level genotypes are available in 575 the external GWAS panel, isoform expression can be directly imputed by multiplying the SNP weights from the predictive model with the genotype dosages in the GWAS panel. If only summary statistics are 576 available, we adopt the weighted burden test from Gusev et al with an ancestry-matched linkage 577 disequilibrium panel^{4,98}. Compared to TWAS, a main distinction for isoTWAS association testing is the 578 increased number of tests (approximately 4-fold the number of isoforms than genes)²¹ and the potential 579 correlation in test statistics for isoforms of the same gene. 580

581

Accordingly, we perform a two-step hypothesis testing framework (**Supplemental Figure S2**)¹⁰². In the first step, for every isoform with a trained model, we generate a TWAS test statistic using either linear regression for GWAS with individual-level genotypes or the weighted burden test for GWAS with only summary statistics⁴. Given the *t* test statistics $T_1, ..., T_t$ for a single gene, we used an omnibus test to aggregate the *t* test statistics into a single P-value for a gene. We benchmark different omnibus tests in

587 simulations, but the default omnibus test in isoTWAS is aggregated Cauchy association test (ACAT)⁴⁹. 588 We control for false discovery across all genes via the Benjamini-Hochberg procedure, but the Bonferroni 589 procedure can also be applied for more conservative false discovery control. In the second step, for 590 isoforms for genes with an adjusted omnibus P < 0.05, we employ Shaffer's modified sequentially 591 rejective Bonferroni (MSRB) procedure to control the within-gene family-wide error rate. At the end of these two steps, we identify a set of genes and their isoforms that are associated with the trait. 592 593 594 Control for false positives within GWAS loci 595 In TWAS and related methods, association statistics have been shown to be well calibrated under the null of no GWAS association. However, within loci harboring significant GWAS signal, false positive 596 associations can result when eQTLs and GWAS coincide within overlapping LD blocks. To address this, 597 we have adopted two conservative approaches to control for type 1 error within GWAS loci, namely (1) 598 permutation testing and (2) probabilistic fine mapping. The permutation testing approach, adopted from 599 Gusev et al⁴, is a highly conservative test of the signal added by the SNP-transcript effects from the 600

601 predictive models, conditional on the GWAS architecture of the locus. Briefly, we shuffle the SNP-

transcript effects in the predictive models 10,000 times and generate a null distribution for the TWAS test statistic for each isoform. We then use this null distribution to generate a permutation-based P-value for the original test statistic for each isoform. Additionally, we aggregate these null distributions using an omnibus test and compare the omnibus P-value to this distribution to generate permutation P-value for each gene. Finally, we can employ isoform-level probabilistic fine-mapping using methods from FOCUS⁵⁵ to generate credible set of isoforms that explain the trait association at a locus. We only run isoform-level fine-mapping for significantly-associated isoforms in overlapping 1 Megabase windows.

609

610 Simulation framework

611 We adopt techniques from Mancuso et al's *twas_sim* protocol¹⁰³ to simulate multivariate isoform 612 expression based on randomly simulated genotypes and environmental random noise. First, for *n* 613 samples, we generate a matrix of genotype dosages for the SNPs within 1 Megabase of 22 different

genes (1 per chromosome) using an LD reference panel of European subjects from 1000 Genomes 614 615 Project⁵¹.

616

617 Next, we generate a matrix of SNP-isoform effects across different causal SNP proportions p_c , numbers of isoforms t, and p_s proportion of the SNP-isoform effects being shared across isoforms of the same 618 gene. We then add two matrices of random noise U and ϵ . The first matrix U noise represents non cis-619 genetic effects on isoforms that are correlated between samples and isoforms; we control the proportion 620 621 of variance explained in isoform expression attributed to U using a parameter σ_h . The second matrix ϵ is a matrix of random noise that is independent for each isoform, such that $\epsilon_i \sim N(0, \sigma_e^2 I)$ where $\sigma_e^2 = 1 - 1$ 622 $\sigma_h - h_g^2$. We generate 10,000 simulations for each configuration of the simulation parameters, varying $n \in$ 623 624 {200, 500}, $p_c \in \{0.001, 0.01, 0.05\}, h_a^2 \in \{0.05, 0.10, 0.25\}, p_s \in \{0, 0.5, 1\}, \text{ and } \sigma_h \in \{0.1, 0.25\}$. Full 625 mathematical details are provided in Supplemental Methods and summarized in Figure 2. 626 We also generate traits under three distinct scenarios, with a continuous trait with heritability $h_t^2 \in$ 627 628 {0.01,0.05,0.10} and a GWAS sample size of 50,000 (**Supplemental Methods**): 1. Only gene-level expression has a non-zero effect on trait. Here, we sum the isoform expression 629 630 to generate a simulated gene expression. We randomly simulate the effect size and scale the error to 631 ensure trait heritability. 632 2. Only 1 isoform has a non-zero effect on the trait. Here, we generate a multivariate isoform 633 expression matrix with 2 isoforms and scale the total gene expression value such that one isoform (called the effect isoform) makes up $p_a \in \{0.10, 0.30, 0.50, 0.70, 0.90\}$ proportion of total gene 634 635 expression. We then generate effect size for one of the isoforms and scale the error to ensure trait 636 heritability. 3. Two isoforms with different effects on traits. Here, we generate a multivariate isoform expression 637 matrix with 2 isoforms that make up equal portions of the total gene expression. We then generate an 638 effect size of α for one isoform and $p_e \alpha$ for the other isoform, such that $p_e \in \{-1, -0.5, -0.2, 0.2, 0.5, 1\}$. 639 We then scale the error to ensure trait heritability. 640 641

642 Lastly, to estimate the approximate false positive rate (FPR), we followed the same simulation framework 643 to generate eQTL data and GWAS data. In the GWAS data, however, we set the effect of gene- and 644 isoform-level imputed expression to 0 to generate a simulated trait under the null, where the gene and 645 isoforms are not associated with the trait. We then estimate the FPR by calculating the proportion of gene-trait associations at P < 0.05 under this null across 20 sets of 1,000 simulated GWAS panels. We 646 also assess isoform-level fine-mapping using FOCUS in a scenario with a gene with 5 or 10 isoforms and 647 a single effect isoform. We compute the sensitivity of 90% credible sets of isoforms (proportion of credible 648 649 sets that contain the effect isoform) and the number of isoforms in the 90% credible set.

650

651 GTEx processing and model training

We quantified GTEx v8³⁷ RNA-Seq samples for 48 tissues using Salmon v1.5.2³² in mapping-based 652 653 mode. We first built a Salmon index for a decoy-aware transcriptome consisting of GENCODE v38 transcript sequences and the full GRCh38 reference genome as decoy sequences²¹. Salmon was then 654 run on FASTQ files with mapping validation and corrections for sequencing and GC bias. We computed 655 50 inferential bootstraps for isoform expression using Salmon's Expectation-Maximization algorithm. We 656 657 then imported Salmon isoform-level quantifications and aggregated to the gene-level using tximeta⁴¹. 658 Using edgeR, gene and isoform-level quantifications underwent TMM-normalization, followed by transformation into a log-space using the variance-stabilizing transformation using DESeq2^{104,105}. We 659 then residualized isoform-level and gene-level expression (as log-transformed CPM) by all tissue-specific 660 covariates (clinical, demographic, genotype PCs, and expression PEER factors) used in the original QTL 661 analyses in GTEx. We calculated the quantification variance across inferential replicates using the 662 computeInfRV() function from the fishpond package¹⁰⁶. We computed the isoform fraction using the 663 isoformTolsoformFraction() function from the IsoformSwitchAnalyzeR package⁵⁴. 664

665

SNP genotype calls were derived from Whole Genome Sequencing data for samples from individuals of European ancestry, filtering out SNPs with minor allele frequency (MAF) less than 5% or that deviated from Hardy-Weinberg equilibrium at P < 10^{-5} . We further filtered out SNPs with MAF less than 1% frequency among the European ancestry samples in 1000 Genomes Project⁵¹.

570	
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	

671	Details of the model training pipeline for GTEx are similar to those summarized in Supplemental Figure
672	\$10 . Gene-level univariate models were trained using elastic net regression ⁴³ , best linear unbiased
673	predictor (BLUP) in a linear mixed model ⁴⁸ , and SuSiE ⁴⁷ , using all SNPs within 1 Mb of the gene
674	body ^{4,43,47,101} . For each gene, the best performing model was chosen based on McNemar's adjusted 5-
675	fold cross-validation (CV) R^2 . We selected only genes with CV $R^2 \ge 0.01$. We applied multivariate
676	modeling outlined in isoTWAS to train isoform-level predictive models, selecting only those isoform
677	models with CV $R^2 \ge 0.01$ (Supplemental Figure S2). All isoTWAS models generated are publicly
678	available (see Data Availability).
679	
680	Developmental brain reference panel processing and model training
681	We quantified developmental frontal cortex ²⁴ (N = 205) RNA-Seq samples using Salmon v1.8.0 ³² in
682	mapping-based mode. We used the same indexed transcriptome as in the GTEx analysis and ran
683	Salmon with mapping validation and corrections for sequencing and GC bias. We computed 50 inferential
684	bootstraps for isoform expression using Salmon's Expectation-Maximization algorithm. We then imported
685	Salmon isoform-level quantifications and aggregated to the gene-level using tximeta ⁴¹ . Using edgeR,
686	gene and isoform-level quantifications underwent TMM-normalization, followed by transformation into a
687	log-space using the variance-stabilizing transformation using DESeq2 ^{104,105} . We then residualized
688	isoform-level and gene-level expression (as log-transformed CPM) by covariates (age, sex, 10 genotype
689	PCs, 90 and 70 hidden covariates with prior, respectively). Typed SNPs with non-zero alternative alleles,
690	MAF > 1%, genotyping rate > 95%, HWE P < 10^{-6} were first imputed to TOPMed Freeze 5 using
691	minimac4 and eagle v2.4 ^{107,108} . We then retained biallelic SNPs with imputation accuracy $R^2 > 0.8$, with
692	rsIDs. Finally, we filtered out SNPs with MAF < 0.05 or that deviated from Hardy-Weinberg equilibrium at
693	P < 10 ⁻⁶ .

694

695 Adult brain reference panel processing and model training

696 Matched genotype and RNAseq data from adult brain cortex tissue from n = 2,365 individuals were

697 compiled and processed from the PsychENCODE Consortium²² and the Accelerating Medicines

Partnership Program for Alzheimer's Disease (AMP-AD)⁵⁶, consisting of the individual studies BipSeq,
BrainGVEX, CommonMind Consortium (CMC), CommonMind Consortium's National Institute of Mental
Health Human Brain Collection Core (CMC HBCC), Lieber Institute for Brain Development-szControl
(LIBD_szControl), UCLA-ASD, Religious Orders Study and the Memory and Aging Project (ROSMAP),
Mount Sinai Brain Bank (MSBB) and MayoRNAseq.

703

Typed genotypes were lifted over to the GRCh38 build using CrossMap v.0.6.3¹⁰⁹ and then filtered to 704 705 remove variants where the reference allele matched any of the alternate alleles. Genotype data from 706 whole genome sequencing (BrainGVEX, UCLA-ASD, ROSMAP, MSBB, and MayoRNAseq) was further 707 filtered to variants present on the Infinium Omni5-4 v1.2 array in order to satisfy the imputation server's maximum limit of 20,000 typed variants per 20Mb. All genotype data was further processed with PLINK 708 v1.90b6.21¹¹⁰, removing variants with HWE P < 10^{-6} , MAF< 0.01 or missingness rate > 0.05, and 709 removing samples with missingness rate > 0.1 across typed variants or missingness rate > 0.5 on any 710 individual chromosome. Genotype data was prepared for imputation using the McCarthy Group's HRC-711 1000G-check-bim-v4.3.0 tool against freeze 8 of the Trans-Omics for Precision Medicine (TOPMed) 712 reference panel¹¹¹. The tool removes A/T and G/C SNPs with MAF > 0.4, variants with alleles that differ 713 714 from the reference panel, variants with an allele frequency difference > 0.2 from the reference panel and variants not in the reference panel. Additionally, the tool updates strand, position and reference/alternate 715 allele assignment to match the reference panel. 716

717

Genotypes were then passed into the TOPMed Imputation Server by individual array batch¹¹². The 718 genotypes were phased with Eagle v2.4 and imputed with Minimac4 using the TOPMed reference 719 panel^{107,108}. Further QC was performed on the imputed genotypes using bcftools v1.11 and PLINK. The 720 721 imputed genotypes were filtered to well-imputed variants with R2 > 0.8. The arrays were merged after 722 filtering to variants that were well-imputed in all arrays to be merged. Only arrays with at least 400,000 723 variants after pre-imputation QC were merged in order to prevent too many variants from dropping out. The merged genotype data was then converted to PLINK 1 binary format and further processed with 724 PLINK, removing variants with duplicates, HWE P < 10^{-6} , MAF < 0.01 or missingness rate > 0.05 and 725

removing samples with missingness rate > 0.1. Samples from the same individual were identified by
 calculating the genetic relatedness matrix using SnpArrays.jl and finding sets of samples with relatedness
 > 0.75. From each set of replicates, only the genotyped sample from the array with the most variants after
 pre-imputation QC was kept. For model training, only SNPs annotated in HapMap3 were retained¹¹³.

RNAseq paired reads from each study were sorted by name and then converted to FASTQ format using 731 samtools v1.14¹¹⁴. The reads were then quantified using salmon v1.8.0 in mapping-based mode using a 732 full decoy indexed from GENCODE v38 transcriptome and GRCh38 patch 13 assembly³². Quantification 733 734 was run using standard EM algorithm with library type automatically inferred and estimates adjusted for 735 sequence-specific and fragment-level GC biases. Bootstrapped abundance estimates were calculated using 50 bootstrap samples. Isoform-level expression was summarized to the gene-level using tximeta¹¹⁵. 736 Only isoforms with 0.1 TPM for more than 75% of samples were retained. The resulting expression was 737 normalized using the variance-stabilizing transformation from DESeg2¹⁰⁵. Samples with WGCNA network 738 connectivity scores of less than -3 were removed as outliers, resulting in a total of 2,115 samples¹¹⁶. 739 740 Isoform- and gene-level expression was then batch-corrected using ComBat, using study site as the batch¹¹⁷. Lastly, age, sex, squared age, 10 genotype PCs, and 200 (for gene expression) and 175 (for 741 742 isoform expression) hidden covariates with prior (using sequencing metrics from PicardTools to estimate the prior) were removed from the expression^{118,119}. The number of hidden covariates with prior (HCP) 743 were selected by optimizing the number of nominal cis-gene-level expression QTLs and cis-isoform-level 744 expression QTLs at Bonferroni-corrected P < 0.05, respectively, on a grid from 100 to 300 HCPs, as 745 detected by QTLtools¹²⁰. 746

747

Details of the model training pipeline are summarized are equivalent to those used to train models in
 GTEx data. All isoTWAS models generated are available at https://zenodo.org/record/6795947⁹².

750

751 Gene- and isoform-level trait mapping

We conducted gene- and isoform-level trait mapping for 15 neuropsychiatric traits: attention-deficit
 hyperactivity disorder (ADHD, N_{cases} = 20,183/N_{controls} = 35,191)⁵⁹, Alzheimer's disease (ALZ,

90,338/1,036,225)⁶⁰, anorexia nervosa (AN, 16,992/55,525)⁷², autism spectrum disorder (ASD, 754 18,381/27,969)⁵⁸, bipolar disorder (BP, 41,917/371,549)⁶¹, brain volume (BV, N = 47,316)⁶², cross-755 disorder (CDG, 232,964/494,162)⁶³, cortical thickness (CortTH, N = 51,665)⁶⁴, intracranial volume (ICV, N 756 = 32,438)⁶⁵, major depressive disorder (MDD, 246,363/561,190)⁶⁶, neuroticism (NTSM, N = 449,484)⁶⁷, 757 obsessive compulsive disorder (OCD, 2,688/7,037)⁶⁸, panic and anxiety disorders (PANIC, 758 2,248/7,992)⁶⁹, post-traumatic stress disorder (PTSD, 32,428/174,227)⁷⁰, and schizophrenia (SCZ, 759 69.369/236.642)⁷¹. For gene-level trait mapping, we used the weighted burden test, followed by the 760 761 permutation test, as outlined by Gusev et al⁴. For isoform-level trait mapping, we used the stage-wise 762 testing procedure outlined in the isoTWAS method. In-sample LD from the QTL reference panels was 763 used to calculate the standard error in the weighted burden test. For isoforms, irrespective of their corresponding genes, passing both stage-wise tests and the permutation test, we employed isoform-level 764 probabilistic fine-mapping using FOCUS with default parameters⁵⁵. These methods are summarized in 765 Supplemental Figure S24. 766 767 We estimated the percent increase in effective sample size by employing the following heuristic. We 768 convert gene-level association P-values into χ^2 test statistics with 1 degree-of-freedom. For $\chi^2 > 1$, we 769 770 then calculate the percent increase for isoTWAS-based associations versus TWAS-based associations. As the mean of the χ^2 distribution is linearly related to power and sample size¹²¹, we can use this percent 771

increase in test statistic as a measure of power or effective sample size. We defined independent 772 genome-wide significant SNPs in GWAS by LD clumping with lead GWAS SNP < 5 x 10⁻⁸ with P-value 773 used for ranking and a R² threshold of 0.2. 774

775

DATA AVAILABILITY 776

777 GTEx genetic, transcriptomic, and covariate data were obtained through dbGAP approval at accession number phs000424.v8.p2. Linkage disequilibrium reference data from the 1000 Genomes Project were 778 779 obtained at this link: https://www.internationalgenome.org/data-portal/sample. GWAS summary statistics were obtained at the following links: ADHD (https://www.med.unc.edu/pgc/download-results/), ALZ 780 (https://ctg.cncr.nl/software/summary statistics/), AN (http://www.med.unc.edu/pgc/results-and-781

- 782 downloads), ASD (https://www.med.unc.edu/pgc/download-results/), BP
- 783 (https://www.med.unc.edu/pgc/download-results/), BV (https://ctg.cncr.nl/software/summary_statistics),
- 784 CDG (https://www.med.unc.edu/pgc/results-and-downloads), CortTH
- 785 (https://enigma.ini.usc.edu/research/download-enigma-gwas-results/), ICV
- 786 (https://enigma.ini.usc.edu/research/download-enigma-gwas-results/), MDD
- 787 (http://dx.doi.org/10.7488/ds/2458), NTSM
- 788 (https://ctg.cncr.nl/software/summary_statistics/neuroticism_summary_statistics), OCD
- 789 (https://www.med.unc.edu/pgc/download-results/), PANIC (https://www.med.unc.edu/pgc/download-
- 790 results/), PTSD (https://www.med.unc.edu/pgc/results-and-downloads/), and SCZ
- 791 (<u>https://www.med.unc.edu/pgc/download-results/</u>). The Developmental Brain RNA-seq and genotype
- 792 dataset from Walker et al is available at dbGAP with accession number phs001900. The subset of Adult
- 793 Brain RNA-seq and genotype data from the PsychENCODE Consortium is available at
- 794 <u>https://psychencode.synapse.org/DataAccess</u> and from AMP-AD is available at
- 795 https://adknowledgeportal.synapse.org/Data%20Access. GWAS summary statistics and accession
- numbers to genotype and RNA-seq data are provided in **Supplemental Table S10**. isoTWAS models for
- 48 tissues from GTEx are available at <u>https://zenodo.org/record/8047940¹²²</u>, adult brain cortex from
- PsychENCODE and AMP-AD are available at https://zenodo.org/record/8048198¹²³, and developmental
- ⁷⁹⁹ brain cortex from Walker et al are available at https://zenodo.org/record/8048137¹²⁴.

800

801 CODE AVAILABILITY

- isoTWAS is available as an R package at <u>https://github.com/bhattacharya-a-bt/isotwas</u>. Sample scripts for
- 803 analyses are available at <u>https://github.com/bhattacharya-a-bt/isotwas manu scripts</u>.

804

805 **REFERENCES**

- Sullivan, P. F. *et al.* Psychiatric Genomics: An Update and an Agenda. *The American journal of psychiatry* **175**, 15–15 (2018).
- Tam, V. *et al.* Benefits and limitations of genome-wide association studies. *Nat Rev Genet* 20, 467–
 484 (2019).

- 3. Gamazon, E. R. et al. A gene-based association method for mapping traits using reference
- 811 transcriptome data. *Nature Genetics* **47**, 1091–1098 (2015).
- 4. Gusev, A. *et al.* Integrative approaches for large-scale transcriptome-wide association studies.
- 813 *Nature Genetics* **48**, 245–252 (2016).
- 5. Barbeira, A. N. *et al.* Exploring the phenotypic consequences of tissue specific gene expression
- variation inferred from GWAS summary statistics. *Nature Communications* **9**, 1–20 (2018).
- 816 6. Hu, Y. *et al.* A statistical framework for cross-tissue transcriptome-wide association analysis. *Nature* 817 *Genetics* 51, 568–576 (2019).
- 7. Zhou, D. *et al.* A unified framework for joint-tissue transcriptome-wide association and Mendelian
 randomization analysis. *Nature Genetics* **52**, 1239–1246 (2020).
- Barbeira, A. N. *et al.* Integrating predicted transcriptome from multiple tissues improves association
 detection. *PLoS Genetics* 15, e1007889 (2019).
- Bhattacharya, A., Li, Y. & Love, M. I. MOSTWAS: Multi-Omic Strategies for Transcriptome-Wide
 Association Studies. *PLOS Genetics* **17**, e1009398 (2021).
- B24 10. Gusev, A. *et al.* Transcriptome-wide association study of schizophrenia and chromatin activity yields
 mechanistic disease insights. *Nature Genetics* **50**, 538–548 (2018).
- 11. Wu, L. *et al.* A transcriptome-wide association study of 229,000 women identifies new candidate
 susceptibility genes for breast cancer. *Nature genetics* **50**, 968–978 (2018).
- Bayesian Test for Colocalisation between Pairs of Genetic Association
 Studies Using Summary Statistics. *PLoS Genetics* **10**, e1004383–e1004383 (2014).
- 13. Gleason, K. J., Yang, F., Pierce, B. L., He, X. & Chen, L. S. Primo: Integration of multiple GWAS and
- omics QTL summary statistics for elucidation of molecular mechanisms of trait-associated SNPs and
 detection of pleiotropy in complex traits. *Genome Biology* 21, 236–236 (2020).
- 14. He, X. et al. Sherlock: Detecting gene-disease associations by matching patterns of expression QTL
- and GWAS. American Journal of Human Genetics **92**, 667–680 (2013).
- 15. Hormozdiari, F. et al. Colocalization of GWAS and eQTL Signals Detects Target Genes. American
- 836 Journal of Human Genetics **99**, 1245–1260 (2016).

16. Umans, B. D., Battle, A. & Gilad, Y. Where Are the Disease-Associated eQTLs? *Trends in Genetics*

838 **37**, 109–124 (2021).

- 839 17. Barrera, L. O. *et al.* Genome-wide mapping and analysis of active promoters in mouse embryonic
 840 stem cells and adult organs. *Genome Res* 18, 46–59 (2008).
- 18. Wang, E. T. *et al.* Alternative isoform regulation in human tissue transcriptomes. *Nature* **456**, 470–
- 842 476 (2008).
- 19. Melé, M. *et al.* The human transcriptome across tissues and individuals. *Science* 348, 660–665
 (2015).
- 20. Merkin, J., Russell, C., Chen, P. & Burge, C. B. Evolutionary dynamics of gene and isoform

regulation in mammalian tissues. *Science* **338**, 1593–1599 (2012).

- 21. Frankish, A. *et al.* GENCODE reference annotation for the human and mouse genomes. *Nucleic*
- 848 Acids Res **47**, D766–D773 (2019).
- 849 22. Gandal, M. J. *et al.* Transcriptome-wide isoform-level dysregulation in ASD, schizophrenia, and
 850 bipolar disorder. *Science* 362, (2018).
- 851 23. Wang, D. *et al.* Comprehensive functional genomic resource and integrative model for the human
 852 brain. *Science* 362, (2018).
- 853 24. RL, W. *et al.* Genetic Control of Expression and Splicing in Developing Human Brain Informs Disease
 854 Mechanisms. *Cell* **179**, 750-771.e22 (2019).
- 25. Leung, S. K. *et al.* Full-length transcript sequencing of human and mouse cerebral cortex identifies
 widespread isoform diversity and alternative splicing. *Cell Rep* **37**, 110022 (2021).
- 26. Li, Y. I. *et al.* RNA splicing is a primary link between genetic variation and disease. *Science* 352,
 600–604 (2016).
- 27. Gandal, M. J. *et al.* Transcriptome-wide isoform-level dysregulation in ASD, schizophrenia, and
 bipolar disorder. *Science* 362, (2018).
- 861 28. Wang, D. *et al.* Comprehensive functional genomic resource and integrative model for the human
 862 brain. *Science* 362, (2018).
- 29. Barbeira, A. N. *et al.* Exploiting the GTEx resources to decipher the mechanisms at GWAS loci.
- 864 Genome Biology 2021 22:1 **22**, 1–24 (2021).

- 30. MM, S. & MS, S. RNA mis-splicing in disease. *Nature reviews. Genetics* **17**, 19–32 (2016).
- 31. Akula, N. et al. Deep transcriptome sequencing of subgenual anterior cingulate cortex reveals cross-
- 867 diagnostic and diagnosis-specific RNA expression changes in major psychiatric disorders.
- 868 Neuropsychopharmacol. **46**, 1364–1372 (2021).
- 32. Patro, R., Duggal, G., Love, M. I., Irizarry, R. A. & Kingsford, C. Salmon provides fast and bias-aware
 guantification of transcript expression. *Nature Methods* 14, 417–419 (2017).
- 33. Bray, N. L., Pimentel, H., Melsted, P. & Pachter, L. Near-optimal probabilistic RNA-seq quantification. *Nat Biotechnol* 34, 525–527 (2016).
- 34. Jaffe, A. E. *et al.* Developmental and genetic regulation of the human cortex transcriptome illuminate
 schizophrenia pathogenesis. *Nat Neurosci* **21**, 1117–1125 (2018).
- 35. Collado-Torres, L. et al. Regional Heterogeneity in Gene Expression, Regulation, and Coherence in
- the Frontal Cortex and Hippocampus across Development and Schizophrenia. *Neuron* **103**, 203216.e8 (2019).
- 36. Jaffe, A. E. *et al.* Profiling gene expression in the human dentate gyrus granule cell layer reveals
 insights into schizophrenia and its genetic risk. *Nat Neurosci* 23, 510–519 (2020).
- 37. Aguet, F. et al. The GTEx Consortium atlas of genetic regulatory effects across human tissues.
- 881 Science **369**, 1318–1330 (2020).
- 38. Breiman, L. & Friedman, J. H. Predicting Multivariate Responses in Multiple Linear Regression.
 Journal of the Royal Statistical Society: Series B (Statistical Methodology) 59, 3–54 (1997).
- 39. Gusev, A. *et al.* Integrative approaches for large-scale transcriptome-wide association studies.
 Nature Genetics 48, 245–252 (2016).
- 40. Gamazon, E. R. *et al.* A gene-based association method for mapping traits using reference
 transcriptome data. *Nature Genetics* 47, 1091–1098 (2015).
- 41. Love, M. I. *et al.* Tximeta: Reference sequence checksums for provenance identification in RNA-seq.
 PLOS Computational Biology **16**, e1007664 (2020).
- 42. Soneson, C., Love, M. I. & Robinson, M. D. Differential analyses for RNA-seq: transcript-level
- estimates improve gene-level inferences. *F1000Research 2015 4:1521* **4**, 1521 (2016).

- 43. Friedman, J., Hastie, T. & Tibshirani, R. Regularization Paths for Generalized Linear Models via
- 893 Coordinate Descent. *Journal of Statistical Software* **33**, 1–22 (2010).
- 44. Rothman, A. J., Levina, E. & Zhu, J. Sparse multivariate regression with covariance estimation.
- Journal of Computational and Graphical Statistics **19**, 947–962 (2010).
- 45. Rauschenberger, A. & Glaab, E. Predicting correlated outcomes from molecular data. *Bioinformatics*37, 3889–3895 (2021).
- 46. Chun, H. & Keleş, S. Sparse partial least squares regression for simultaneous dimension reduction
 and variable selection. *J R Stat Soc Series B Stat Methodol* **72**, 3–25 (2010).
- 47. Wang, G., Sarkar, A., Carbonetto, P. & Stephens, M. A simple new approach to variable selection in
- 901 regression, with application to genetic fine mapping. *Journal of the Royal Statistical Society: Series B*902 82, 1273–1300 (2020).
- 48. Endelman, J. B. Ridge Regression and Other Kernels for Genomic Selection with R Package rrBLUP.
 The Plant Genome 4, 250–255 (2011).
- 49. Liu, Y. *et al.* ACAT: A Fast and Powerful p Value Combination Method for Rare-Variant Analysis in
 Sequencing Studies. *Am J Hum Genet* **104**, 410–421 (2019).
- 50. Van den Berge, K., Soneson, C., Robinson, M. D. & Clement, L. stageR: a general stage-wise
- method for controlling the gene-level false discovery rate in differential expression and differential
 transcript usage. *Genome Biology 2017 18:1* 18, 1–14 (2017).
- 51. Auton, A. *et al.* A global reference for human genetic variation. *Nature* vol. 526 68–74 Preprint at
 https://doi.org/10.1038/nature15393 (2015).
- 52. Cao, C. *et al.* Power analysis of transcriptome-wide association study: Implications for practical
 protocol choice. *PLoS Genetics* **17**, e1009405–e1009405 (2021).
- 53. Cao, C. *et al.* Power analysis of transcriptome-wide association study: Implications for practical
 protocol choice. *PLoS Genetics* **17**, e1009405 (2021).
- 916 54. Vitting-Seerup, K. & Sandelin, A. IsoformSwitchAnalyzeR: analysis of changes in genome-wide
- patterns of alternative splicing and its functional consequences. *Bioinformatics* **35**, 4469–4471
- 918 (2019).

- 919 55. Mancuso, N. et al. Probabilistic fine-mapping of transcriptome-wide association studies. Nature
- 920 *Genetics* **51**, 675–682 (2019).
- 56. Vialle, R. A., de Paiva Lopes, K., Bennett, D. A., Crary, J. F. & Raj, T. Integrating whole-genome
- 922 sequencing with multi-omic data reveals the impact of structural variants on gene regulation in the
- 923 human brain. *Nat Neurosci* **25**, 504–514 (2022).
- 57. RL, W. et al. Genetic Control of Expression and Splicing in Developing Human Brain Informs Disease
- 925 Mechanisms. *Cell* **179**, 750-771.e22 (2019).
- 58. Grove, J. *et al.* Identification of common genetic risk variants for autism spectrum disorder. *Nature genetics* 51, 431–444 (2019).
- 59. Demontis, D. *et al.* Discovery of the first genome-wide significant risk loci for attention
- 929 deficit/hyperactivity disorder. *Nature Genetics* **51**, 63–75 (2019).
- 930 60. Jansen, I. E. *et al.* Genome-wide meta-analysis identifies new loci and functional pathways
 931 influencing Alzheimer's disease risk. *Nature Genetics* **51**, 404–413 (2019).
- 61. Mullins, N. *et al.* Genome-wide association study of more than 40,000 bipolar disorder cases
 provides new insights into the underlying biology. *Nat Genet* 53, 817–829 (2021).
- 62. Jansen, P. R. *et al.* Genome-wide meta-analysis of brain volume identifies genomic loci and genes
 shared with intelligence. *Nat Commun* **11**, 5606 (2020).
- 63. Genomic relationships, novel loci, and pleiotropic mechanisms across eight psychiatric disorders.
 Cell **179**, 1469-1482.e11 (2019).
- 64. Grasby, K. L. *et al.* The genetic architecture of the human cerebral cortex. *Science* 367, eaay6690
 (2020).
- 65. Adams, H. H. *et al.* Novel genetic loci underlying human intracranial volume identified through
 genome-wide association. *Nat Neurosci* **19**, 1569–1582 (2016).
- 942 66. Howard, D. M. et al. Genome-wide meta-analysis of depression identifies 102 independent variants
- and highlights the importance of the prefrontal brain regions. *Nature Neuroscience* 22, 343–352
 (2019).
- 945 67. Nagel, M. et al. Meta-analysis of genome-wide association studies for neuroticism in 449,484
- 946 individuals identifies novel genetic loci and pathways. *Nat Genet* **50**, 920–927 (2018).

- 947 68. Arnold, P. D. et al. Revealing the complex genetic architecture of obsessive-compulsive disorder
- 948 using meta-analysis. *Molecular Psychiatry* 23, 1181–1188 (2018).
- 69. Forstner, A. J. *et al.* Genome-wide association study of panic disorder reveals genetic overlap with
- neuroticism and depression. *Mol Psychiatry* **26**, 4179–4190 (2021).
- 951 70. Nievergelt, C. M. et al. International meta-analysis of PTSD genome-wide association studies
- identifies sex- and ancestry-specific genetic risk loci. *Nat Commun* **10**, 4558 (2019).
- 71. Trubetskoy, V. *et al.* Mapping genomic loci implicates genes and synaptic biology in schizophrenia.
 Nature 604, 502–508 (2022).
- 955 72. Watson, H. J. et al. Genome-wide association study identifies eight risk loci and implicates metabo-

psychiatric origins for anorexia nervosa. *Nat Genet* **51**, 1207–1214 (2019).

- 957 73. Prive, F., Aschard, H., Ziyatdinov, A. & Blum, M. G. B. Efficient analysis of large-scale genome-wide
 958 data with two R packages: Bigstatsr and bigsnpr. *Bioinformatics* 34, 2781–2787 (2018).
- 74. Consortium, T. S. W. G. of the P. G., Ripke, S., Walters, J. T. & O'Donovan, M. C. Mapping genomic
 loci prioritises genes and implicates synaptic biology in schizophrenia. 2020.09.12.20192922 Preprint
 at https://doi.org/10.1101/2020.09.12.20192922 (2020).
- 75. Lek, M. *et al.* Analysis of protein-coding genetic variation in 60,706 humans. *Nature* 536, 285–291
 (2016).
- 76. Karczewski, K. J. *et al.* The mutational constraint spectrum quantified from variation in 141,456
 humans. *Nature* 581, 434–443 (2020).
- 966 77. Li, Y. I. *et al.* Annotation-free quantification of RNA splicing using LeafCutter. *Nat Genet* 50, 151–158
 967 (2018).
- 78. Du, P. *et al.* Comparison of Beta-value and M-value methods for quantifying methylation levels by
 microarray analysis. *BMC Bioinformatics* **11**, 587–587 (2010).
- 970 79. van Iterson, M., van Zwet, E. W., Heijmans, B. T. & Heijmans, B. T. Controlling bias and inflation in
- 971 epigenome- and transcriptome-wide association studies using the empirical null distribution. *Genome*972 *Biology* 18, 19–19 (2017).
- 80. Schrode, N. *et al.* Synergistic effects of common schizophrenia risk variants. *Nat Genet* **51**, 1475–
 1485 (2019).

- 81. Bhattacharjee, S. et al. A Subset-Based Approach Improves Power and Interpretation for the
- Combined Analysis of Genetic Association Studies of Heterogeneous Traits. *Am J Hum Genet* **90**,
 821–835 (2012).
- 978 82. O'Donnell-Luria, A. H. et al. Heterozygous Variants in KMT2E Cause a Spectrum of
- 979 Neurodevelopmental Disorders and Epilepsy. *Am J Hum Genet* **104**, 1210–1222 (2019).
- 83. Reay, W. R. & Cairns, M. J. Pairwise common variant meta-analyses of schizophrenia with other
- psychiatric disorders reveals shared and distinct gene and gene-set associations. *Transl Psychiatry*10, 1–11 (2020).
- 983 84. Nishioka, K. et al. PR-Set7 Is a Nucleosome-Specific Methyltransferase that Modifies Lysine 20 of

Histone H4 and Is Associated with Silent Chromatin. *Molecular Cell* **9**, 1201–1213 (2002).

- 985 85. Schmidt-Kastner, R., Guloksuz, S., Kietzmann, T., van Os, J. & Rutten, B. P. F. Analysis of GWAS-
- Derived Schizophrenia Genes for Links to Ischemia-Hypoxia Response of the Brain. *Front Psychiatry*11, 393 (2020).
- 86. Wong, H. *et al.* Isoform-specific roles for AKT in affective behavior, spatial memory, and extinction
 related to psychiatric disorders. *eLife* 9, e56630 (2020).
- 990 87. Howell, K. R., Floyd, K. & Law, A. J. PKBy/AKT3 loss-of-function causes learning and memory
- deficits and deregulation of AKT/mTORC2 signaling: Relevance for schizophrenia. *PLoS One* 12,
 e0175993 (2017).
- 88. Chen, H.-Y. & Maher, B. J. Lost in Translation: Cul3-Dependent Pathological Mechanisms in
 Psychiatric Disorders. *Neuron* 105, 398–399 (2020).

89. Pouget, J. G. The Emerging Immunogenetic Architecture of Schizophrenia. *Schizophrenia Bulletin*44, 993–1004 (2018).

997 90. Liu, D. *et al.* Rare schizophrenia risk variant burden is conserved in diverse human populations.

- 998 2022.01.03.22268662 Preprint at https://doi.org/10.1101/2022.01.03.22268662 (2022).
- 999 91. The GIT Family of Proteins Forms Multimers and Associates with the Presynaptic Cytomatrix Protein
- 1000 Piccolo* Journal of Biological Chemistry. https://www.jbc.org/article/S0021-9258(20)86625-3/fulltext.
- 1001 92. Bhattacharya, A. isoTWAS models using 48 GTEx tissues and PsychENCODE data (07.04.22).
- 1002 (2022) doi:10.5281/zenodo.6795947.

- 1003 93. Qi, T. et al. Genetic control of RNA splicing and its distinct role in complex trait variation. Nat Genet
- 1004 (2022) doi:10.1038/s41588-022-01154-4.
- 1005 94. Delaneau, O. et al. A complete tool set for molecular QTL discovery and analysis. Nature
- 1006 *Communications* **8**, (2017).
- 1007 95. Schwarz, T. *et al.* Powerful eQTL mapping through low coverage RNA sequencing.
- 1008 2021.08.08.455466 Preprint at https://doi.org/10.1101/2021.08.08.455466 (2021).
- 96. Doose, G., Bernhart, S. H., Wagener, R. & Hoffmann, S. DIEGO: detection of differential alternative
 splicing using Aitchison's geometry. *Bioinformatics* 34, 1066–1068 (2018).
- 1011 97. Veturi, Y. & Ritchie, M. D. How powerful are summary-based methods for identifying expression-trait
- 1012 associations under different genetic architectures? in *Pacific Symposium on Biocomputing* vol. 0
- 1013 228–239 (World Scientific Publishing Co. Pte Ltd, 2018).
- 1014 98. Bhattacharya, A. *et al.* Best practices for multi-ancestry, meta-analytic transcriptome-wide association
- 1015 studies: lessons from the Global Biobank Meta-analysis Initiative. *medRxiv* **3**, 2021.11.24.21266825-
- 1016 2021.11.24.21266825 (2021).
- 1017 99. Zhu, A. *et al.* MRLocus: Identifying causal genes mediating a trait through Bayesian estimation of
 1018 allelic heterogeneity. *PLOS Genetics* **17**, e1009455–e1009455 (2021).
- 1019 100. Whalen, S., Schreiber, J., Noble, W. S. & Pollard, K. S. Navigating the pitfalls of applying
 1020 machine learning in genomics. *Nat Rev Genet* 23, 169–181 (2022).
- 1021 101. Endelman, J. B. Ridge Regression and Other Kernels for Genomic Selection with R Package
 1022 rrBLUP. *The Plant Genome* 4, 250–255 (2011).
- 1023 102. Van den Berge, K., Soneson, C., Robinson, M. D. & Clement, L. stageR: a general stage-wise
 1024 method for controlling the gene-level false discovery rate in differential expression and differential
 1025 transcript usage. *Genome Biology 2017 18:1* 18, 1–14 (2017).
- 1026 103. Wang, X., Lu, Z., Bhattacharya, A., Pasaniuc, B. & Mancuso, N. twas_sim, a Python-based tool
- for simulation and power analysis of transcriptome-wide association analysis. *Bioinformatics* 39,
 btad288 (2023).
- 1029 104. Ritchie, M. E. *et al.* limma powers differential expression analyses for RNA-sequencing and
 microarray studies. *Nucleic Acids Research* 43, e47–e47 (2015).

- 1031 105. Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion for RNA-1032 seq data with DESeq2. *Genome Biology* **15**, 550–550 (2014).
- 1033 106. Zhu, A., Srivastava, A., Ibrahim, J. G., Patro, R. & Love, M. I. Nonparametric expression analysis 1034 using inferential replicate counts. *Nucleic Acids Research* **47**, e105 (2019).
- 1035 107. Kowalski, M. H. et al. Use of >100,000 NHLBI Trans-Omics for Precision Medicine (TOPMed)
- 1036 Consortium whole genome sequences improves imputation quality and detection of rare variant
- 1037 associations in admixed African and Hispanic/Latino populations. *PLoS Genetics* **15**, e1008500–
- 1038 e1008500 (2019).
- 1039 108. Loh, P. R. *et al.* Reference-based phasing using the Haplotype Reference Consortium panel.
 Nature Genetics 48, 1443–1448 (2016).
- 1041 109. Zhao, H. *et al.* CrossMap: a versatile tool for coordinate conversion between genome assemblies.
 1042 *Bioinformatics* **30**, 1006–1007 (2014).
- 1043 110. Purcell, S. *et al.* PLINK: A Tool Set for Whole-Genome Association and Population-Based
 1044 Linkage Analyses. *Am. J. Hum. Genet* 81, 559–575 (2007).
- 1045 111. Taliun, D. *et al.* Sequencing of 53,831 diverse genomes from the NHLBI TOPMed Program.
 1046 *Nature* 590, 290–299 (2021).
- 1047 112. Das, S. *et al.* Next-generation genotype imputation service and methods. *Nature Genetics* 48,
 1048 1284–1287 (2016).
- 1049 113. Belmont, J. W. et al. The international HapMap project. Nature 426, 789–796 (2003).
- 1050 114. Li, H. *et al.* The Sequence Alignment/Map format and SAMtools. *Bioinformatics* 25, 2078–2079
 1051 (2009).
- 1052 115. Love, M. I. *et al.* Tximeta: Reference sequence checksums for provenance identification in RNA 1053 seq. *PLOS Computational Biology* **16**, e1007664–e1007664 (2020).
- 1054 116. WGCNA: an R package for weighted correlation network analysis | BMC Bioinformatics | Full
- 1055 Text. https://bmcbioinformatics.biomedcentral.com/articles/10.1186/1471-2105-9-559.
- 1056 117. Leek, J. T. & Storey, J. D. Capturing Heterogeneity in Gene Expression Studies by Surrogate
- 1057 Variable Analysis. *PLoS Genetics* **3**, e161–e161 (2007).

- 1058 118. Mostafavi, S. et al. Normalizing RNA-Sequencing Data by Modeling Hidden Covariates with Prior
- 1059 Knowledge. *PLoS ONE* **8**, e68141–e68141 (2013).
- 1060 119. Picard toolkit. (2018).
- 1061 120. Delaneau, O. et al. A complete tool set for molecular QTL discovery and analysis. Nature
- 1062 *Communications* **8**, (2017).
- 1063 121. Zhang, W. et al. Integrative transcriptome imputation reveals tissue-specific and shared biological
- 1064 mechanisms mediating susceptibility to complex traits. *Nature Communications* **10**, 3834–3834
- 1065 (2019).
- 1066 122. Bhattacharya, A. isoTWAS models for 48 GTEx models (06/2023). (2023)
- 1067 doi:10.5281/zenodo.8047940.
- 1068 123. Bhattacharya, A. isoTWAS models for adult brain cortex (06/2023). (2023)
- 1069 doi:10.5281/zenodo.8048198.
- 1070 124. Bhattacharya, A. isoTWAS models for developmental brain cortex (06/2023). (2023)
- 1071 doi:10.5281/zenodo.8048137.
- 1072
- 1073

1074 FIGURE LEGENDS

1075 Figure 1: Isoform-centric approach for complex trait mapping and prioritization of disease mechanisms at 1076 a genetic locus, (a) Motivation for isoTWAS. Gene G has three isoforms associated with a trait but only one has an effect on the trait. Gene G itself does not show an association with the trait. Studying genetic 1077 associations with an isoform-centric perspective will prioritize Gene G, but not with a gene-centric 1078 1079 perspective. (b) Schematic comparison of isoTWAS and TWAS. First, isoTWAS differs from TWAS by 1080 training a multivariate model of isoform expression, while TWAS models total gene expression, the sum of 1081 isoform expression. Second, isoTWAS maps isoform-trait associations through a step-wise hypothesis testing framework that provides gene-level false discovery control and isoform-level family-wide error rate 1082 control. TWAS only maps gene-trait association. 1083

1084

1085 Figure 2: IsoTWAS models predict gene expression with more accuracy than TWAS models in simulated 1086 data. (a) Simulation setup to generate isoform expression with specified isoQTL architecture, controlled 1087 expression heritability, number of isoforms, and inter-isoform correlation structure. (b) Proportion of 1088 simulations where the isoTWAS model has the maximum adjusted R² for marginal isoform prediction (Yaxis) across shared isoQTL proportion (X-axis), colored by isoTWAS method, facetted by causal isoQTL 1089 proportion (top margin) and proportion of isoform expression variance attributed to shared non cis-genetic 1090 effects (right margin). (c) Boxplots of difference in adjusted R² in predicting gene expression between 1091 1092 isoTWAS and TWAS models from simulations with sample size 500 where isoform and gene expression 1093 heritability are set to 0.05, across causal isoQTL proportion (X-axis) and colored by number of transcripts 1094 per gene, facetted by proportion of shared isoQTLs (top margin) and proportion of variance explained by 1095 shared non cis-genetic effects (right margin).

1096

1097 Figure 3: Multivariate isoform-level predictive models improve upon gene-level predictive models in predictive gene-level expression. (a) Barplot showing the number of isoforms with CV $R^2 > 0.01$ (Y-axis) 1098 using multivariate (cream) and univariate (blue) modelling methods across brain tissues (X-axis). (b) 1099 1100 Boxplot of median percent difference in predicting isoform expression (Y-axis) using multivariate 1101 compared to univariate method by brain and other tissue (X-axis). P-value corresponds to difference in 1102 median across groups, adjusted for sample size. (c) Barplot showing the number of genes passing CV 1103 thresholds (Y-axis) using TWAS (red) and isoTWAS (blue) across brain tissues. (d) Barplot showing the 1104 number of genes with CV R² > 0.01 (Y-axis) using TWAS (red) and isoTWAS (blue) across brain tissues 1105 (X-axis). (e) Boxplot of percent difference in R² (Y-axis) of predicting gene expression (isoTWAS – TWAS) in external datasets. X-axis shows the training and imputation datasets. The median percent 1106 1107 difference in labelled.

1108

Figure 4: IsoTWAS improves power to detect gene-trait associations, especially when genetic effects
 differ across isoforms, in simulations. (a) Power to detect gene-trait association (proportion of tests with P
 < 2.5 x 10⁻⁶, Y-axis) across causal proportion of isoQTLs (X-axis), facetted by proportion of shared
 isoQTLs (top margin) and proportion of variance explained by shared non cis-genetic effects (right

margin). (b) Power to detect gene-trait association (proportion of tests with $P < 2.5 \times 10^{-6}$, Y-axis) across 1113 1114 proportion of gene expression explained by effect isoform (X-axis). (c) Power to detect gene-trait association (proportion of tests with $P < 2.5 \times 10^{-6}$, Y-axis) across ratio of effect sizes for 2 effect isoforms. 1115 1116 Across all plots, isoform and total gene expression heritability is set to 0.05 and causal proportion of 0.01 in (b-c). Points are colored by method and shaped by the number of isoforms per gene. 1117 1118 Figure 5: Isoform-level trait mapping increases discovery of genetic associations over gene-level trait 1119 1120 mapping. (a) Schematic diagram for trait mapping using gene-level TWAS and isoTWAS using 1121 PsychENCODE data. (b) Number of gene-trait associations overlapping GWAS risk SNPs within 0.5 Mb 1122 using gene-level TWAS (red), isoTWAS (blue), or either (green) at conservative permutation-based 1123 significance thresholds. (c) Scatterplot of standardized effect sizes (Z-scores) using isoTWAS and gene-1124 level TWAS, considered associations with nominal P < 0.05 using both TWAS and isoTWAS. Gray line shows the 45-degree line and the green line shows an ordinary least squares regression. (d) Empirical 1125 Bayes estimate of test statistic inflation (X-axis) for TWAS (red) and isoTWAS (red) gene-level 1126 associations across 15 traits (Y-axis). (e) Mean percent increase in approximate χ^2 -test statistic (squared 1127 1128 Z-score), which is proportional to increase in effective sample size, for isoTWAS trait associations over 1129 TWAS trait associations. (f) Number of gene-trait associations overlapping GWAS risk SNPs within 0.5 Mb using splicing-event-based TWAS (purple), isoTWAS (blue), or either (green) at conservative 1130 permutation-based significance thresholds. 1131

1132

Figure 6: *isoTWAS implicates isoforms of AKT3, CUL3, HSPD1, and PCLO in genetic associations with psychiatric traits.* In each plot, (top) Manhattan plots of GWAS risk, total gene eQTLs, and isoQTLs, colored by LD to the lead isoQTL and lead isoQTL shown in a triangle and labelled. LD is based on the 1000 Genomes European reference. (bottom) Boxplots of gene and isoform expression by genotype of the lead isoQTL SNP and forest plot of the lead isoQTL's effect and 95% confidence interval on the trait, gene, and isoform, with P-values labelled. (a) SCZ risk, *AKT3* gene expression, and ENST00000492957 isoform expression. (b) SCZ risk, *CUL3* gene expression, ENST00000409096 isoform expression. (c)

- 1140 SCZ risk, HSPD1 gene expression, ENST00000678969 isoform expression. (d) CDG risk, PCLO gene
- 1141 expression, ENST00000423517 isoform expression.
- 1142

1143 SUPPLEMENTAL INFORMATION

- 1144 Supplemental Methods
- 1145 Supplemental Methods are provided in the attached SupplementalMethods.pdf.
- 1146

1147 Supplemental Figure Legends

Figure S1: Directed acyclic graph (DAG) illustrating causal assumptions in isoTWAS. We assume that the local genetic variants within 1 Megabase of a gene have direct effects on the expression of a gene G and its isoforms; these genetic effects need not be shared across isoforms and the gene. Furthermore, we assume that the abundance of a gene is the sum of abundances of its isoforms. Lastly, we assume that the isoform and gene need not affect the complex trait through the same path. We also acknowledge that genetic variants may have effects on the trait through pathways independent of gene and isoform expression.

1155

1156 Figure S2: Step-wise hypothesis testing in isoTWAS. First, isoform-trait associations are estimated either using appropriate regressions of imputed expression in individual-level GWAS or the weighted burden 1157 test in Gusev et al in GWAS summary statistics. Then, associations for isoforms of the same gene are 1158 aggregated to the gene-level using the Aggregated Cauchy Association Test (ACAT). These aggregated 1159 gene-level associations are adjusted for multiple testing burden to control the false discovery rate (FDR) 1160 using either a Bonferroni or Benjamini-Hochberg procedure. Lastly, for isoforms of genes that pass gene-1161 level testing, we control the family-wide error rate (FWER) using Shaffer's modified sequentially rejective 1162 1163 procedure.

1164

Figure S3: Comparison of predictive performance of 6 models implemented in isoTWAS. Across 1,000 simulations of 5 isoforms with isoform heritability (h_i^2) set to 0.05 or 0.10. Boxplots of adjusted R² of prediction of isoform expression (Y-axis) across shared isoQTL proportion (X-axis)

1	168	3
---	-----	---

1100	
1169	Figure S4: IsoTWAS models predict gene expression with more accuracy than TWAS models. Boxplots
1170	of percent difference in adjusted R ² in predicting gene expression between isoTWAS and TWAS models
1171	from simulations with sample size 200 (compare with sample size 500 in Figure 2), where isoform and
1172	gene expression heritability are set to (top) 0.05 and (bottom) 0.10.
1173	
1174	Figure S5: Across 48 GTEx tissues (Y-axis), the number of multivariate (cream) and univariate (blue)
1175	models predicting isoform expression at CV $R^2 > 0.01$ (X-axis).
1176	
1177	Figure S6: Across 48 GTEx tissues (Y-axis), percent difference in CV R ² (X-axis) of prediction of isoform
1178	expression models using multivariate models versus univariate models. The label shows the proportion of
1179	isoforms with improved performance using multivariate models.
1180	
1181	Figure S7: Number of isoforms with CV $R^2 > 0.01$ (Y-axis) using the baseline univariate model (teal, best
1182	univariate) and 4 multivariate models.
1183	
1184	Figure S8: Across 48 GTEx tissues (Y-axis), number of genes that pass TWAS (blue) and isoTWAS (red)
1185	CV R ² cutoffs to be available for testing in the trait-mapping step (X-axis)
1186	
1187	Figure S9: Across 48 GTEx tissues (Y-axis), percent difference in CV R ² (X-axis) of prediction of isoform
1188	expression models using multivariate models versus univariate models. The label shows the proportion of
1189	isoforms with improved performance using multivariate models.
1190	
1191	Figure S10: Across 48 GTEx tissues (Y-axis), number of genes predicted at CV R ² > 0.01 using TWAS
1192	(blue) and isoTWAS (red)
1193	
1194	Figure S11: Number of genes (left) and isoforms (right) predicted at CV R ² > 0.01 using isoTWAS across
1195	48 GTEx tissues.

11	96
----	----

1197	Figure S12: Performance of isoTWAS across number of isoforms per gene across 48 GTEx tissues. (a)
1198	Ratio of number of isoforms predicted at $R^2 > 0.01$ using multivariate versus univariate prediction. (b)
1199	Ratio of number of genes passing CV threshold using isoTWAS versus TWAS. (c) Median number of
1200	isoforms predicted at CV R ² > 0.01 in isoTWAS models across increasing number of isoforms per gene.
1201	The red line shows the line $Y = X + 1$. (d) Ratio of number of genes with CV $R^2 > 0.01$ using isoTWAS
1202	versus TWAS.
1203	
1204	Figure S13: Performance of isoTWAS across increasing maximum isoform fraction across 48 GTEx
1205	tissues. (a) Ratio of number of isoforms predicted at $R^2 > 0.01$ using multivariate versus univariate
1206	prediction. (b) Ratio of number of genes passing CV threshold using isoTWAS versus TWAS. (c) Ratio of
1207	number of genes with CV $R^2 > 0.01$ using isoTWAS versus TWAS.
1208	
1209	Figure S14: Performance of isoTWAS across increasing gene length across 48 GTEx tissues. (a) Ratio
1210	of number of isoforms predicted at $R^2 > 0.01$ using multivariate versus univariate prediction. (b) Ratio of
1211	number of genes passing CV threshold using isoTWAS versus TWAS. (c) Ratio of number of genes with
1212	CV $R^2 > 0.01$ using isoTWAS versus TWAS. $R^2 > 0.01$ using isoTWAS versus TWAS.
1213	
1214	Figure S15: Performance of isoTWAS across increasing SNP density across 48 GTEx tissues. (a) Ratio
1215	of number of isoforms predicted at $R^2 > 0.01$ using multivariate versus univariate prediction. (b) Ratio of
1216	number of genes passing CV threshold using isoTWAS versus TWAS. (c) Ratio of number of genes with
1217	CV $R^2 > 0.01$ using isoTWAS versus TWAS.
1218	
1219	Figure S16: Performance of isoTWAS across increasing sample size across 48 GTEx tissues. (a) Ratio
1220	of number of isoforms predicted at $R^2 > 0.01$ using multivariate versus univariate prediction. (b) Ratio of
1221	number of genes passing CV threshold using isoTWAS versus TWAS. (c) Ratio of number of genes with
1222	CV $R^2 > 0.01$ using isoTWAS versus TWAS.
1223	

- 1224 Figure S17: Performance of isoTWAS across proportion of shared isoTWAS model effect SNPs across
- 48 GTEx tissues. (a) Ratio of number of isoforms predicted at $R^2 > 0.01$ using multivariate versus
- univariate prediction. (b) Ratio of number of genes passing CV threshold using isoTWAS versus TWAS.
- 1227 (c) Ratio of number of genes with CV $R^2 > 0.01$ using isoTWAS versus TWAS.

1228

- 1229 **Figure S18**: Performance of isoTWAS across increasing mean counts of isoforms and genes across 48
- 1230 *GTEx tissues.* (a) Ratio of number of isoforms predicted at $R^2 > 0.01$ using multivariate versus univariate
- 1231 prediction across increasing mean counts of isoforms. (b) Ratio of number of genes with CV R² > 0.01
- 1232 using isoTWAS versus TWAS across increasing mean counts of genes.
- 1233

Figure S19: Performance of isoTWAS across increasing quantification variance of isoforms and genes across 48 GTEx tissues. (a) Ratio of number of isoforms predicted at $R^2 > 0.01$ using multivariate versus univariate prediction across increasing quantification variance of isoforms. (b) Ratio of number of genes with CV $R^2 > 0.01$ using isoTWAS versus TWAS across increasing quantification variance of genes.

1238

Figure S20: (a) Median percent difference in R² of predicting original isoform expression using multivariate versus univariate models across increasing number of isoforms per gene, colored by models trained in the original dataset (pink) and the leave-one-out dataset (teal) (b) Median percent difference in R² of predicting original gene expression using isoTWAS versus TWAS models across increasing number of isoforms per gene, colored by models trained in the original dataset (pink) and the leave-one-out dataset (teal)

1245

Figure S21: *IsoTWAS and gene-level TWAS show relatively similar false positive rates.* Across 20 iterations of 1,000 simulations, boxplots of false positive rate to detect a gene-trait association using Cauchy-aggregated P-values of isoform-trait associations (red) and gene-level TWAS (blue). In these simulations, we simulate 200 and 5,000 samples in the eQTL and GWAS panels, 5 isoforms, and isoform and gene expression heritability of 0.10. We vary the causal isoQTLs proportion (p_c, shown on X-axis), the QTL architecture (right margin), and correlation between isoforms (top margin). For each iteration, we

simulate one eQTL panel and 1,000 GWAS panels where genetically-regulated gene and isoform
expression have no effect on the trait. We calculate the false positive rate as the proportion of the 1,000
tests that give P > 0.05.

1255

Figure S22: Power comparison between TWAS and isoTWAS in detecting gene-trait association across 3 1256 scenarios (Methods). (a) Power to detect gene-trait association (proportion of tests with $P < 2.5 \times 10^{-6}$, Y-1257 axis) across number of total isoforms per gene (X-axis), facetted by proportion of shared isoQTLs (top 1258 1259 margin) and proportion of expression heritability attributed to shared non-genetic effects across isoforms 1260 (right margin). Points are shaped by causal isoQTL proportion and colored by method. (b) Power to 1261 detect gene-trait association (proportion of tests with $P < 2.5 \times 10^{-6}$, Y-axis) across proportion of gene 1262 expression explained by effect isoform (X-axis), facetted by proportion of shared isoQTLs (top margin) 1263 and proportion of expression heritability attributed to shared non-genetic effects across isoforms (right margin). Points are shaped by number of isoforms per gene and colored by method. (c) Power to detect 1264 gene-trait association (proportion of tests with $P < 2.5 \times 10^{-6}$, Y-axis) across ratio of effect sizes of 2 effect 1265 isoforms (X-axis), facetted by proportion of shared isoQTLs (top margin) and proportion of expression 1266 1267 heritability attributed to shared non-genetic effects across isoforms (right margin). Points are shaped by 1268 number of isoforms per gene and colored by method. Here, expression heritability is set of 0.05, trait heritability is set to 0.1, and causal proportion of (b-c) is set of 0.01. 1269

1270

Figure S23: Sensitivity (a) and mean set size (b) of 90% credible set using FOCUS to finemap isoformtrait associations for a single gene, across causal isoQTL proportion (X-axis). Points are colored by trait heritability and shaped by the number of isoforms per gene. Plots are facetted by proportion of shared isoQTLs (top margin) and proportion of expression heritability attributed to shared non-genetic effects across isoforms (right margin). Line-range shows a 95% jackknife confidence interval.

1276

Figure S24: Schematic diagram for analysis using adult and developmental frontal cortex data from
 PsychENCODE and AMP-AD. Data sources for eQTL reference data, GWAS cohorts, and reference LD

1279	data are provided on the left (black). The full gene-level TWAS (red) and isoTWAS (blue) are summarized
1280	on the right.
1281	
1282	Figure S25: Number of gene-trait associations (Y-axis) using TWAS (red) and isoTWAS (blue) across
1283	trait (X-axis), faceting by tissue (top margin) and threshold (right margin: adjusted $P < 0.05$ and
1284	permutation P < 0.05, top; in 90% credible set using FOCUS fine-mapping, bottom).
1285	
1286	Figure S26: Number of isoform-trait associations (Y-axis) using isoTWAS across trait (X-axis), faceting by
1287	tissue (top margin) and threshold (right margin: adjusted P < 0.05 and permutation P < 0.05, top; in 90%
1288	credible set using FOCUS fine-mapping, bottom).
1289	
1290	Figure S27: QQ-plots of gene-level P-values using TWAS (red) and isoTWAS (blue) across 15 traits.
1291	
1292	Figure S28: (a) Distribution of number of genes in risk region (left) and in 90% credible set (right) using
1293	TWAS and isoTWAS. (b) Distribution of number of isoforms per gene in risk region (left) and in 90%
1294	credible set (right) using isoTWAS.
1295	
1296	Figure S29: Lollipop plot of enrichment ratio (X-axis) of ontologies (Y-axis) for isoTWAS-prioritized genes
1297	associated at adjusted P < 0.05 and permutation P < 0.05. Points are shaped by tissue type (adult or
1298	developmental) and colored by ontology type (biological process, cell component, molecular function).
1299	
1300	Figure S30: For ENST00000681794 association with BV (a) and ENST00000492957 with BV (b),
1301	Manhattan plots of GWAS, eQTL, and isoQTL signal colored by LD (top), boxplots of gene (red) and
1302	isoform (blue) expression (Y-axis) by genotype (X-axis) (bottom left), and forest plot of lead isoQTL
1303	association with isoform (blue), gene (red), and trait (black) (bottom right). (c) Comparison of exon and
1304	intron structure of ENST00000681794 and ENST00000492957, based on Gencode v38 reference.
1305	
1306	Supplemental Tables

1307 Table S1: Sample size, source, and tissues for functional genomics reference panels 1308 Table S2: Number of genes/models that pass cross-validation prediction cutoffs using TWAS and 1309 1310 isoTWAS feature selection criteria and prediction methods 1311 Table S3: Distribution of predictive external R2 of observed total gene expression vs. predicted total gene 1312 expression (isoTWAS -TWAS) 1313 1314 1315 Table S4: Number of GWAS loci with an isoTWAS-, TWAS-, and splice-TWAS-prioritized gene within 0.5 1316 Mb 1317 **Table S5**: TWAS and fine-mapping results for genes with adjusted P < 0.05 and permutation P < 0.051318 across 15 traits using adult brain cortex models 1319 1320 **Table S6**: isoTWAS and fine-mapping results for genes with adjusted P < 0.05 and permutation P < 0.051321 1322 across 15 traits using adult brain cortex models 1323 **Table S7**: TWAS and fine-mapping results for genes with adjusted P < 0.05 and permutation P < 0.051324 across 15 traits using developmental brain cortex models 1325 1326 **Table S8:** isoTWAS and fine-mapping results for genes with adjusted P < 0.05 and permutation P < 0.051327 across 15 traits using developmental brain cortex models 1328 1329 1330 **Table S9**: Empirical bayes estimates of test statistic inflation and increase in χ^2 test statistics of gene-1331 level associations using isoTWAS and TWAS 1332 Table S10: Accession numbers and URLs for data access 1333 1334

1335	Supplemental Data
1336	Data 1: Predictive performance comparison of isoTWAS multivariate methods in simulated data across a
1337	variety of genetic architecture settings
1338	
1339	Data 2: Predictive performance comparison of isoTWAS and TWAS gene expression prediction in
1340	simulated data across a variety of genetic architecture settings
1341	
1342	Data 3: Isoform expression prediction metrics across a variety of factors, using 48 GTEx datasets
1343	
1344	Data 4: Gene expression prediction metrics across a variety of factors, using 48 GTEx datasets
1345	
1346	Data 5 : False positive rates using isoTWAS and TWAS to detect a gene-trait association at $P < 0.05$
1347	across a variety genetic architecture parameters
1348	
1349	Data 6 : Power to detect trait association at $P < 2.5 \times 10^{-6}$ across 1,000 simulations each for 22 genes
1350	using TWAS and isoTWAS across various simulations. These simulations are under Scenario 1 in Figure
1351	4a (gene has a true effect on the trait, but none of the isoforms have a true effect on the trait)
1352	
1353	Data 7 : Power to detect trait association at $P < 2.5 \times 10^{-6}$ across 1,000 simulations each for 22 genes
1354	using TWAS and isoTWAS (ACAT) across various simulations. These simulations are under Scenario 2
1355	in Figure 4b (a gene has multiple isoforms, only one has an effect on the trait, and we vary the usage of
1356	this effect isoform)
1357	
1358	Data 8 : Power to detect trait association at $P < 2.5 \times 10^{-6}$ across 1,000 simulations each for 22 genes
1359	using TWAS and isoTWAS (ACAT) across various simulations. These simulations are under Scenario 3
1360	in Figure 4c (a gene has two isoforms with differing effects on the trait, and we vary the effect size of one
1361	of the isoforms)
1362	

1363	Data 9: Sensitivity and mean set size of 90% credible sets determined by FOCUS in simulated data
1364	across a variety of genetic architecture parameters
1365	
1366	Data 10: Raw TWAS results across 15 neuropsychiatric traits using adult brain cortex expression models
1367	
1368	Data 11: Raw isoTWAS results across 15 neuropsychiatric traits using adult brain cortex expression
1369	models
1370	
1371	Data 12: Raw TWAS results across 15 neuropsychiatric traits using developmental brain cortex
1372	expression models
1373	
1374	Data 13: Raw isoTWAS results across 5 neuropsychiatric traits using developmental brain cortex
1375	expression models
1376	
1377	Data 14: GWAS and nominal eQTL and isoQTL summary statistics corresponding to isoTWAS isoform-
1378	trait association examples shown in Figure 7 and Supplemental Figure S30.
1379	
1380	
1381	ACKNOWLEDGEMENTS
1382	We thank Kangcheng Hou, Tommer Schwarz, Vidhya Venkateswaran, Pan Zhang, Leanna Hernandez,
1383	Nathan LaPierre, Harold Pimentel, Mike Love, and Achal Patel for engaging discussion during the
1384	research process. We thank Kanishka Patel for her aesthetic advice for figures. We thank the Psychiatric
1385	Genomics Consortium and Complex Trait Genomics Lab for their publicly available GWAS summary
1386	statistics.
1387	
1388	BP was partially supported by NIH awards R01 HG009120, R01 MH115676, R01 CA251555, R01
1389	AI153827, R01 HG006399, R01 CA244670, and U01 HG011715. MJG was supported by SFARI Bridge
1390	to Independence Award, NIMH R01-MH121521, NIMH R01-MH123922, and NICHD-P50-HD103557.

1391

1392 AUTHOR INFORMATION

- 1393 Contributions
- 1394 Conceptualization: AB, BP, MJG; Methodology: AB, BP, MJG; Software: AB; Validation: AB; Formal
- analysis: AB, MK, CW, CJ; Investigation: AB, MJG; Resources: BP, MJG; Data curation: AB, MK, CW,
- 1396 CJ, MJG; Writing original draft: AB, MJG; Writing reviewing and editing: AB, MK, CW, CJ, BP, MJG;
- 1397 Visualization: AB; Supervision: BP, MJG; Project administration: BP, MJG; Funding acquisition: BP, MJG

1398

1399 Correspondence

- 1400 Please direct all correspondence to Arjun Bhattacharya (abtbhatt@ucla.edu).
- 1401

1402 ETHICS DECLARATIONS

- 1403 Competing Interests
- 1404 The authors declare no competing interests.




Figure 1: *Isoform-centric approach for complex trait mapping and prioritization of disease mechanisms at a genetic locus.* (a) Motivation for isoTWAS. Gene G has three isoforms associated with a trait but only one has an effect on the trait. Gene G itself does not show an association with the trait. Studying genetic associations with an isoform-centric perspective will prioritize Gene G, but not with a gene-centric perspective. (b) Schematic comparison of isoTWAS and TWAS. First, isoTWAS differs from TWAS by training a multivariate model of isoform expression, while TWAS models total gene expression, the sum of isoform expression. Second, isoTWAS maps isoform-trait associations through a step-wise hypothesis testing framework that provides gene-level false discovery control and isoform-level family-wide error rate control. TWAS only maps gene-trait association.






Figure 2: *IsoTWAS models predict gene expression with more accuracy than TWAS models in simulated data.* (a) Simulation setup to generate isoform expression with specified isoQTL architecture, controlled expression heritability, number of isoforms, and inter-isoform correlation structure. (b) Proportion of simulations where the isoTWAS model has the maximum adjusted R² for marginal isoform prediction (Y-axis) across shared isoQTL proportion (X-axis), colored by isoTWAS method, facetted by causal isoQTL proportion (top margin) and proportion of isoform expression variance attributed to shared non cis-genetic effects (right margin). (c) Boxplots of difference in adjusted R² in predicting gene expression between isoTWAS and TWAS models from simulations with sample size 500 where isoform and gene expression heritability are set to 0.05, across causal isoQTL proportion (X-axis) and colored by number of transcripts per gene, facetted by proportion of shared isoQTLs (top margin) and proportion of variance explained by shared non cis-genetic effects (right margin).





Figure 3: *Multivariate isoform-level predictive models improve upon gene-level predictive models in predictive gene-level expression.* (a) Barplot showing the number of isoforms with $CV R^2 > 0.01$ (Y-axis) using multivariate (cream) and univariate (blue) modelling methods across brain tissues (X-axis). (b) Boxplot of median percent difference in predicting isoform expression (Y-axis) using multivariate compared to univariate method by brain and other tissue (X-axis). P-value corresponds to difference in median across groups, adjusted for sample size. (c) Barplot showing the number of genes passing CV thresholds (Y-axis) using TWAS (red) and isoTWAS (blue) across brain tissues. (d) Barplot showing the number of genes with $CV R^2 > 0.01$ (Y-axis) using TWAS (red) and isoTWAS (blue) across brain tissues. (X-axis). (e) Boxplot of percent difference in R^2 (Y-axis) of predicting gene expression (isoTWAS – TWAS) in external datasets. X-axis shows the training and imputation datasets. The median percent difference in labelled.



Number of isoforms • 2 ▲ 5 ■ 10 Method • TWAS • isoTWAS

Figure 4: *IsoTWAS improves power to detect gene-trait associations, especially when genetic effects differ across isoforms, in simulations.* (a) Power to detect gene-trait association (proportion of tests with $P < 2.5 \times 10^6$, Y-axis) across causal proportion of isoQTLs (X-axis), facetted by proportion of shared isoQTLs (top margin) and proportion of variance explained by shared non cis-genetic effects (right margin). (b) Power to detect gene-trait association (proportion of tests with $P < 2.5 \times 10^{-6}$, Y-axis) across proportion of tests with $P < 2.5 \times 10^{-6}$, Y-axis) across proportion of gene expression explained by effect isoform (X-axis). (c) Power to detect gene-trait association (proportion of tests with $P < 2.5 \times 10^{-6}$, Y-axis) across ratio of effect sizes for 2 effect isoforms. Across all plots, isoform and total gene expression heritability is set to 0.05 and causal proportion of 0.01 in (b-c). Points are colored by method and shaped by the number of isoforms per gene.




Figure 5: *Isoform-level trait mapping increases discovery of genetic associations over gene-level trait mapping.* (a) Schematic diagram for trait mapping using gene-level TWAS and isoTWAS using PsychENCODE data. (b) Number of gene-trait associations overlapping GWAS risk SNPs within 0.5 Mb using gene-level TWAS (red), isoTWAS (blue), or either (green) at conservative permutation-based significance thresholds. (c) Scatterplot of standardized effect sizes (Z-scores) using isoTWAS and gene-level TWAS, considered associations with nominal P < 0.05 using both TWAS and isoTWAS. Gray line shows the 45-degree line and the green line shows an ordinary least squares regression. (d) Empirical Bayes estimate of test statistic inflation (X-axis) for TWAS (red) and isoTWAS (red) gene-level associations across 15 traits (Y-axis). (e) Mean percent increase in approximate χ^2 -test statistic (squared Z-score), which is proportional to increase in effective sample size, for isoTWAS trait associations over TWAS trait associations. (f) Number of gene-trait associations overlapping GWAS risk SNPs within 0.5 Mb using splicing-event-based TWAS (purple), isoTWAS (blue), or either (green) at conservative permutation-based significance thresholds.

medRxiv preprint doi: https://doi.org/10.1101/2022.08.23.22279134; this version posted July 6, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license .




Figure 6: *isoTWAS implicates isoforms of AKT3, CUL3, HSPD1, and PCLO in genetic associations with psychiatric traits.* In each plot, (top) Manhattan plots of GWAS risk, total gene eQTLs, and isoQTLs, colored by LD to the lead isoQTL and lead isoQTL shown in a triangle and labelled. LD is based on the 1000 Genomes European reference. (bottom) Boxplots of gene and isoform expression by genotype of the lead isoQTL SNP and forest plot of the lead isoQTL's effect and 95% confidence interval on the trait, gene, and isoform, with P-values labelled. **(a)** SCZ risk, *AKT3* gene expression, and ENST00000492957 isoform expression. **(b)** SCZ risk, *CUL3* gene expression, ENST00000409096 isoform expression. **(c)** SCZ risk, *HSPD1* gene expression, ENST00000678969 isoform expression. **(d)** CDG risk, *PCLO* gene expression, ENST00000423517 isoform expression.